var title_f8_15_8432="Contents: Hypertension";
var content_f8_15_8432=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hypertension",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hypertension",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Definition and types",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/13/5338\">",
"           Approach to the patient with hypertension and hypokalemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43080\">",
"           Blood pressure measurement in the diagnosis and management of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/26/422\">",
"           Initial evaluation of the hypertensive adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1543\">",
"           Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/2/29737\">",
"           Blood pressure management in patients with atherosclerotic cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18068\">",
"           Can therapy be discontinued in well-controlled hypertension?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20218\">",
"           Choice of therapy in essential hypertension: Clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36314\">",
"           Choice of therapy in primary (essential) hypertension: Recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36728\">",
"           Definition, risk factors, and evaluation of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/14/19685\">",
"           Differences between angiotensin converting enzyme inhibitors and receptor blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/4/4169\">",
"           Hypertension: Who should be treated?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32966\">",
"           Major side effects and safety of calcium channel blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18473\">",
"           Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/36/32330\">",
"           Overview of hypertension in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23828\">",
"           Patient adherence and the treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/17/33046\">",
"           Perioperative management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/60/19398\">",
"           Renal effects of ACE inhibitors in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25224\">",
"           Renin-angiotensin system inhibition in the treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/41/4755\">",
"           The prevalence and control of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13027\">",
"           Thiazides versus loop diuretics in treatment of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/62/2021\">",
"           Treatment of hypertension in asthma and COPD",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/14/15592\">",
"           Treatment of hypertension in blacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21210\">",
"           Treatment of hypertension in patients with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29031\">",
"           Treatment of hypertension in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/27/25018\">",
"           Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35256\">",
"           Treatment of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/63/15350\">",
"           Use of thiazide diuretics in patients with primary hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14149\">",
"           Vasopeptidase inhibition in the management of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/40/33417\">",
"           What is goal blood pressure in the treatment of hypertension?",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1827\">",
"           Withdrawal syndromes with antihypertensive therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         End-organ damage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36825\">",
"           Actions of angiotensin II on the heart",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17305\">",
"           Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37685\">",
"           Cardiovascular risks of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/42/6824\">",
"           Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/34/17959\">",
"           Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/19/25914\">",
"           Clinical manifestations and diagnosis of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18247\">",
"           Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20261\">",
"           Effect of antihypertensive treatment on renal function in essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3285\">",
"           Electrocardiographic diagnosis of left ventricular hypertrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/23/1401\">",
"           Left ventricular hypertrophy and arrhythmia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/54/25449\">",
"           Management of aortic dissection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21859\">",
"           Ocular effects of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37859\">",
"           Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/23/16761\">",
"           Hypertension after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/15/8436\">",
"           Hypertension following erythropoietin in chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30582\">",
"           Hypertension in autosomal dominant polycystic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/46/20202\">",
"           Hypertension in dialysis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36804\">",
"           Low-renin essential (primary) hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42674\">",
"           NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/61/34770\">",
"           Neurovascular abnormalities in the pathogenesis of primary (essential) hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7337\">",
"           Overview of hypertension in acute and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38874\">",
"           Overview of the risks and benefits of alcohol consumption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/35/39477\">",
"           Possible role of low birth weight in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypertensive emergencies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18853\">",
"           Drug treatment of hypertensive emergencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/27/41398\">",
"           Malignant hypertension and hypertensive encephalopathy in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28246\">",
"           Management of severe asymptomatic hypertension (hypertensive urgencies)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29130\">",
"           Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/56/32650\">",
"           Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/11/18614\">",
"           Treatment of specific hypertensive emergencies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Monitoring",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7113\">",
"           Ambulatory blood pressure monitoring and white coat hypertension in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nonpharmacologic therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/30/38375\">",
"           Cardiovascular effects of caffeine",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/43/42679\">",
"           Diet in the treatment and prevention of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/9/8345\">",
"           Dietary therapy for obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33866\">",
"           Drug therapy of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/2998\">",
"           Exercise in the treatment and prevention of hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34630\">",
"           Obesity and weight reduction in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13060\">",
"           Potassium and hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/35/24120\">",
"           Salt intake, salt restriction, and essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3395\">",
"           Smoking and hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/63/3060\">",
"           Essential hypertension in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9159\">",
"           Genetic factors in the pathogenesis of essential hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11174\">",
"           Hypertensive complications in blacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/12/26823\">",
"           Increased pulse pressure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/40/44677\">",
"           Prehypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Resistant hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/55/36728\">",
"           Definition, risk factors, and evaluation of resistant hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/27/35256\">",
"           Treatment of resistant hypertension",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Secondary hypertension",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33433\">",
"           Chronic kidney disease associated with atherosclerotic renovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37911\">",
"           Clinical features of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34471\">",
"           Clinical manifestations and diagnosis of fibromuscular dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/31001\">",
"           Establishing the diagnosis of renovascular hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/23/7544\">",
"           Evaluation of acute decompensated heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36214\">",
"           Paroxysmal hypertension (pseudopheochromocytoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28503\">",
"           Pathophysiology of cardiogenic pulmonary edema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/54/21351\">",
"           Pheochromocytoma in genetic disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/54/8040\">",
"           Treatment of bilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/0/26631\">",
"           Treatment of fibromuscular dysplasia of the renal arteries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/54/32616\">",
"           Treatment of pheochromocytoma in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40199\">",
"           Treatment of primary aldosteronism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29369\">",
"           Treatment of unilateral atherosclerotic renal artery stenosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/21/27991\">",
"           Who should be evaluated for renovascular or other causes of secondary hypertension?",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3EB19E1F31-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_15_8432=[""].join("\n");
var outline_f8_15_8432=null;
var title_f8_15_8433="Electroanatomic atrial tachy II";
var content_f8_15_8433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic map of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The activation map, in the right anterior oblique projection, was obtained by electroanatomic mapping during atrial tachycardia. The earliest activation, shown in red (arrow), represents the origin of the tachycardia located in the posterolateral right atrium in the region of the crista terminalis. The impulse spreads from this focus (yellow to green to blue), to activate the rest of the right atrium. The last part to be activated is the region around the superior vena cave (SVC) (deep blue).",
"    <div class=\"footnotes\">",
"     TA: tricuspid annulus; IVC: inferior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Marchlinski, F, Callans, D, Gottleib, C, et al, Pacing Clin Electrophysiol 1998; 21:1621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8433=[""].join("\n");
var outline_f8_15_8433=null;
var title_f8_15_8434="Patient information: Activity during pregnancy (The Basics)";
var content_f8_15_8434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/2/4131\">",
"         Patient information: How to tell when labor starts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/52/35650\">",
"         Patient information: Preterm labor (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Activity during pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/activity-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H16206725\">",
"      <span class=\"h1\">",
"       What do I need to do differently while I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During pregnancy, most women can be as active as they were before they got pregnant. This includes traveling, working, exercising, and having sex. If you have any questions about doing an activity during pregnancy, be sure to ask your doctor or midwife.",
"     </p>",
"     <p>",
"      Women with certain conditions might need to limit their activity. If your doctor or midwife thinks you should limit your activity, he or she will let you know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258415797\">",
"      <span class=\"h1\">",
"       Travel",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women can drive and travel by car throughout their pregnancy. But when traveling by car, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Always wear your seat belt. The shoulder belt should go between your breasts and to the side of your belly. The lap belt should go under your belly.",
"       </li>",
"       <li>",
"        Take plenty of breaks during long trips. Be sure to stop often so that you can walk and stretch your legs.",
"       </li>",
"       <li>",
"        Keep the car&rsquo;s air bags turned on.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Women can also travel by plane during pregnancy. But if you are planning to fly toward the end of your pregnancy, check with the airline. Most airlines don&rsquo;t allow women to fly during their last month of pregnancy.",
"     </p>",
"     <p>",
"      During long flights, be sure to shift your position while seated, and move your legs and feet often. You should also stand up and move around when it is safe to do so. This can prevent blood clots from forming in your legs.",
"     </p>",
"     <p>",
"      If you are planning to travel to another country, let your doctor or midwife know. In some countries, infection is a concern. Ask your doctor or midwife whether you can safely go there. For example, many health care providers recommend that pregnant women not travel to places in the world where malaria is common.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258415812\">",
"      <span class=\"h1\">",
"       Exercise",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors recommend that all adults, including pregnant women, get at least 30 minutes of exercise on all or most days of the week.",
"     </p>",
"     <p>",
"      Exercise has many benefits during pregnancy. It can help with your mood, energy level, and sleep. It can also help with pregnancy symptoms such as constipation, bloating, swelling, and back pain.",
"     </p>",
"     <p>",
"      The type of exercise that is right for you depends on your current pregnancy, past pregnancies, and how active you were before you got pregnant.",
"     </p>",
"     <p>",
"      In general, doctors usually recommend walking and swimming as good types of exercise for pregnant women. Pregnant women should avoid activities in which they could easily fall or hurt their belly. These include hockey, soccer, basketball, horseback riding, downhill skiing, and gymnastics.",
"     </p>",
"     <p>",
"      To exercise safely, you should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid lying flat on your back (after the first 3 months of pregnancy)",
"       </li>",
"       <li>",
"        Start off slowly and slowly increase your level of activity",
"       </li>",
"       <li>",
"        Avoid exercising in hot or humid weather",
"       </li>",
"       <li>",
"        Drink plenty of water",
"       </li>",
"       <li>",
"        Wear a bra that supports your breasts",
"       </li>",
"       <li>",
"        Stop exercising if you get out of breath and can&rsquo;t talk easily",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should stop exercising and let your doctor or midwife know if you have any of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding from the vagina",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling light-headed or dizzy",
"       </li>",
"       <li>",
"        A headache or chest pain",
"       </li>",
"       <li>",
"        Muscle weakness",
"       </li>",
"       <li>",
"        Contractions",
"       </li>",
"       <li>",
"        Fluid leaking from vagina",
"       </li>",
"       <li>",
"        Leg swelling, pain, redness, or warmth",
"       </li>",
"       <li>",
"        Not feeling your baby move as much as usual",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258415827\">",
"      <span class=\"h1\">",
"       Work",
"      </span>",
"      &nbsp;&mdash;&nbsp;Whether or not you should stop working depends on your health, your baby&rsquo;s health, and what your work involves.",
"     </p>",
"     <p>",
"      Women who have no problems during pregnancy can usually work up until they go into labor. But it depends on your job and what it involves.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258415842\">",
"      <span class=\"h1\">",
"       Sex",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women can keep having sex during a normal pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H258415857\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=see_link\">",
"       Patient information: How to tell when labor starts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       Patient information: Preterm labor (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?8/15/8434?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85378 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8434=[""].join("\n");
var outline_f8_15_8434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16206725\">",
"      What do I need to do differently while I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258415797\">",
"      Travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258415812\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258415827\">",
"      Work",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258415842\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258415857\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8435="Sincalide: Drug information";
var content_f8_15_8435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sincalide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/26/16803?source=see_link\">",
"    see \"Sincalide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kinevac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraction of gallbladder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.02 mcg/kg over 30-60 seconds; may repeat in 15 minutes with a 0.04 mcg/kg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infusion: 0.12 mcg/kg in 100 mL of  NS; administer over 50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 0.1 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pancreatic function:",
"     </b>",
"     I.V.: 0.02 mcg/kg over 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Accelerate barium transit through small bowel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 0.04 mcg/kg over 30-60 seconds; if movement of barium has not occurred in 30 minutes, may repeat dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infusion: 0.12 mcg/kg in 30 mL of NS; administer over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kinevac&reg;: 5 mcg [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration via infusion may help manage some adverse events or increase GI tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. push: Administer over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion: Administer over 30-50 minutes. For pancreatic testing, administer over 30 minutes beginning after secretin infusion is started.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postevacuation cholecystography; gallbladder bile sampling; stimulate pancreatic secretion for analysis; accelerate the transit of barium through the small bowel",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestional: Abdominal pain (20%), cramps, nausea (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Central nervous system: Dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Diaphoresis, diarrhea, dyspnea, fecal urgency, flushing, headache, hyper-/hypotension, numbness, rash, sneezing, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2528945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sincalide or any component of the formulation; intestinal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2528946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obstruction: Some risk of evacuating small gallstones into cystic duct or common bile duct and obstructing flow.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Use with caution in pregnancy; may induce premature labor (especially if near term) or spontaneous abortion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Solution for injection contains sodium metabisulfite which may cause allergic reactions in some individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2528942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Because of its effect on smooth muscle, use during pregnancy should be avoided (may cause spontaneous abortion or premature labor). Use during pregnancy only if clearly needed. Should not be administered near term; may induce labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2528944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknow/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16571175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sincalide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering sincalide to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Kinevac Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg (1): $95.34",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2528956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For cholecystography, xrays are taken at 5-minute intervals after the injection. For visualization of the cystic duct, xrays may be required at 1-minute intervals for the first 5 minutes after injection.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2528954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gallbladder size: &ge;40% reduction considered a satisfactory contraction.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates contraction of the gallbladder; inhibits gastric emptying by causing pyloric contraction, and increases intestinal motility; stimulates pancreatic secretion; causes smooth muscle contraction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Contraction of the gallbladder: ~5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10266 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-197.136.42.3-93F80B87AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8435=[""].join("\n");
var outline_f8_15_8435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221382\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221390\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221383\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221384\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221373\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221363\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221375\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221374\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221388\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528945\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528946\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300044\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222940\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221371\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528942\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528944\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16571175\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323859\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528956\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528954\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221366\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221377\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10266\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10266|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/26/16803?source=related_link\">",
"      Sincalide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8436="Hypertension following erythropoietin in chronic kidney disease";
var content_f8_15_8436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertension following erythropoietin in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8436/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8436/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8436/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/15/8436/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 30 percent of patients who receive erythropoietin (EPO) intravenously for the anemia of chronic kidney disease may develop an elevation in diastolic pressure of 10 mmHg or more [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, the blood pressure (BP) is less likely to rise after subcutaneous administration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;How EPO therapy may raise the blood pressure is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/4\">",
"     4",
"    </a>",
"    ]. Several factors that may contribute to the hypertensive response have been identified. These include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/4-17\">",
"     4-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High dose of EPO",
"     </li>",
"     <li>",
"      Prior personal or family history of hypertension",
"     </li>",
"     <li>",
"      Diminished production of nitric oxide",
"     </li>",
"     <li>",
"      Marked increase in intracytosolic calcium levels",
"     </li>",
"     <li>",
"      Enhanced vascular alpha adrenergic sensitivity",
"     </li>",
"     <li>",
"      Increased plasma endothelin levels",
"     </li>",
"     <li>",
"      Arterial remodeling through stimulation of vascular cell growth",
"     </li>",
"     <li>",
"      Activation of the renin-angiotensin system",
"     </li>",
"     <li>",
"      Elevation of the thromboxane:prostacyclin ratio in vascular tissue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study, for example, examined the effects of erythropoietin upon vascular responsiveness to norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/5\">",
"     5",
"    </a>",
"    ]. Intraarterial infusions of norepinephrine in anemic patients on hemodialysis caused a decrease in forearm blood flow and an increase in forearm vascular resistance that was significantly less than that found in healthy controls. Repeat studies performed after 6 and 12 weeks of erythropoietin therapy demonstrated that vascular responsiveness to norepinephrine had been restored to values equal to or greater than the control subjects. Mean arterial pressure also significantly increased during erythropoietin therapy. An almost fourfold increase in vasoconstrictor sensitivity to alpha adrenergic stimuli was also evident in the venous circulation of erythropoietin-treated hemodialysis patients compared with healthy subjects, but vasorelaxation in response to bradykinin was unchanged in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/16\">",
"     16",
"    </a>",
"    ]. Of note, erythropoietin infusion into hand veins of healthy subjects produced no vasoconstriction.",
"   </p>",
"   <p>",
"    From a hemodynamic viewpoint, the elevation in BP is consistent with rapid reversal of anemia-induced peripheral vasodilatation with a less than complete reversal of the anemia-induced rise in cardiac output. Why this occurs in not well understood, but impaired myocardial compliance resulting from the cardiac hypertrophy commonly seen in uremia may be an important factor. In elderly patients treated with EPO, the high cardiac output gradually falls over a period of one year and is accompanied by a 25 percent reduction in left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the other end of the spectrum, some chronically hypotensive dialysis patients show an improvement in blood pressure following EPO therapy. However, this does not appear to be associated with a lessening of hemodynamic instability during dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, antiplatelet agents may reduce the risk of EPO-induced hypertension. In one study, for example, the incidence of hypertension after EPO was only six percent in patients treated with one of these drugs as compared to 56 percent in those not receiving antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/20\">",
"     20",
"    </a>",
"    ]. Why this might occur is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPERTENSIVE ENCEPHALOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive encephalopathy sometimes accompanied by seizures may occur when EPO causes a rapid rise in BP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/21\">",
"     21",
"    </a>",
"    ]. Hyperperfusion of the cerebral circulation due to a breakdown of cerebral autoregulation may be important in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/8\">",
"     8",
"    </a>",
"    ]. It is not possible to predict in advance who will develop this complication; as a result, prodromal symptoms (such as persistent headache or visual disturbances) must be looked for, particularly in previously normotensive individuals in the early weeks and months after the institution of EPO therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure must be closely monitored in all patients with chronic kidney disease, particularly during initiation with EPO. Therapy of EPO-induced hypertension begins with prevention. The risk of hypertension can be ameliorated by raising the hematocrit",
"    <strong>",
"     slowly",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/22\">",
"     22",
"    </a>",
"    ]. If there has been a rapid rise in the hemoglobin levels, there may be a reduction in the EPO dose.",
"   </p>",
"   <p>",
"    The risk may also be lessened by aiming for the current target levels for hemoglobin, which are 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    The CREATE study reported a greater than 50 percent increase in risk for developing hypertension in patients targeted to a hemoglobin of 13 to 15",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    compared with those targeted to 10.5 to",
"    <span class=\"nowrap\">",
"     11/5",
"    </span>",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/23\">",
"     23",
"    </a>",
"    ]. A meta-analysis on nine studies, which included the CREATE study, also reported a higher risk of poorly-controlled blood pressure in patients targeted to higher hemoglobin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who still become hypertensive can be treated with fluid removal (via dialysis or, if the patient has only chronic kidney disease, diuretics) and the administration of antihypertensive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8436/abstract/25\">",
"     25",
"    </a>",
"    ]. Beta-adrenergic blockers and vasodilators should be considered as agents of first choice, although calcium channel blockers and angiotensin converting enzyme inhibitors also may be effective. The dose of EPO should be reduced or discontinued for several weeks in severe cases or when other therapeutic measures are ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25671830\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure increases of 10 mmHg or more have been noted in 20 to 30 percent of patients who receive intravenous erythropoietin (EPO) for the anemia of chronic kidney disease. Subcutaneous EPO administration is less likely to have this effect. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism(s) explaining hypertension resulting from EPO administration is unclear. However, altered vascular responsivity to circulating vasoconstrictors and vasodilators combined with impaired myocardial compliance are likely participants. Higher targeted hemoglobin levels are also associated with poorer blood pressure control. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of EPO-induced hypertension begins with prevention. The risk of hypertension can be ameliorated by raising the hematocrit",
"      <strong>",
"       slowly",
"      </strong>",
"      . If there has been a rapid rise in the hemoglobin levels, there may be a reduction in the EPO dose. The risk may also be lessened by aiming for the current target levels for hemoglobin, which are 10 to 11",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Patients who still become hypertensive can be treated with fluid removal (via dialysis or, if the patient has only chronic kidney disease, diuretics) and the administration of antihypertensive agents. The dose of EPO should be reduced or discontinued for several weeks in severe cases or when other therapeutic measures are ineffective. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevention and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/1\">",
"      Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/2\">",
"      Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15:3154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/3\">",
"      Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/4\">",
"      Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/5\">",
"      Hand MF, Haynes WG, Johnstone HA, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/6\">",
"      Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/7\">",
"      Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/8\">",
"      Ishimitsu T, Tsukada H, Ogawa Y, et al. Genetic predisposition to hypertension facilitates blood pressure elevation in hemodialysis patients treated with erythropoietin. Am J Med 1993; 94:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/9\">",
"      Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/10\">",
"      Marrero MB, Venema RC, Ma H, et al. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int 1998; 53:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/11\">",
"      Brochu E, Lacasse S, Larivi&egrave;re R, et al. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 1999; 10:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/12\">",
"      Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 2004; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/13\">",
"      Lerche D, Schmidt R, Zoellner K, et al. Rheology in whole blood and in red blood cells under recombinant human erythropoietin therapy. Contrib Nephrol 1989; 76:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/14\">",
"      Anastassiades E, Howarth D, Howarth J, et al. Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin. Nephrol Dial Transplant 1993; 8:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/15\">",
"      Vaziri ND. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol 2008; 4:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/16\">",
"      Abiose AK, Aronow WS, Moreno H Jr, et al. Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin. Am J Ther 2007; 14:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/17\">",
"      Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/18\">",
"      Martinez-Vea A, Bardaj&iacute; A, Garc&iacute;a C, et al. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/19\">",
"      Onoyama K, Hori K, Osato S, Fujishima M. Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients. Nephrol Dial Transplant 1991; 6:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/20\">",
"      Caravaca F, Pizarro JL, Arrobas M, et al. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 1994; 45:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/21\">",
"      Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/22\">",
"      Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/23\">",
"      Dr&uuml;eke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/24\">",
"      Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8436/abstract/25\">",
"      Novak BL, Force RW, Mumford BT, Solbrig RM. Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy 2003; 23:265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1979 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8436=[""].join("\n");
var outline_f8_15_8436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25671830\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPERTENSIVE ENCEPHALOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25671830\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8437="Oxacillin: Drug information";
var content_f8_15_8437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxacillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/56/900?source=see_link\">",
"    see \"Oxacillin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"    see \"Oxacillin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F204193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"     I.V.: 2 g every 4 hours with gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     I.M., I.V.: 250-500 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection:",
"     </b>",
"     I.V.: 2 g every 4 hours with rifampin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 1-2 g every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus,",
"      </i>",
"     </b>",
"     <b>",
"      methicillin-susceptible infections, including brain abscess, bursitis, erysipelas, mastitis, mastoiditis, osteomyelitis, perinephric abscess, pneumonia, pyomyositis, scalded skin syndrome, toxic shock syndrome:",
"     </b>",
"     I.V.: 2 g every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F204208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"      see \"Oxacillin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Arthritis (septic):",
"     </b>",
"     I.V.: 37 mg/kg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011), moderate-to-severe infection,",
"      <b>",
"       <i>",
"        S. aureus",
"       </i>",
"      </b>",
"      (methicillin-susceptible) (preferred):",
"     </b>",
"     Infants &gt;3 months and Children: I.V.: 150-200 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Epiglottitis:",
"     </b>",
"     I.V.: 150-200 mg/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     I.M., I.V.: 100-150 mg/kg/day in divided doses every 6 hours (maximum: 4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 150-200 mg/kg/day in divided doses every 6 hours (maximum: 12 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Staphylococcal scalded-skin syndrome:",
"     </b>",
"     I.V.: 150 mg/kg/day divided every 6 hours for 5-7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F204194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F204195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Clinical practice varies; some clinicians recommend adjustment to the lower range of the usual dosage as based on severity of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution: 1 g (50 mL); 2 g (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F204171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer around-the-clock to promote less variation in peak and trough serum levels. Administer IVP over 10 minutes. Administer IVPB over 30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F204222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     W, hetastarch 6%, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, cyclophosphamide, cyclosporine, diltiazem, famotidine, fluconazole, foscarnet, heparin, hydrocortisone sodium succinate, hydromorphone, labetalol, levofloxacin, magnesium sulfate, meperidine, methotrexate, milrinone, morphine, oxytocin, potassium chloride, tacrolimus, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, sodium bicarbonate, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Caffeine citrate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F204170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections such as osteomyelitis, septicemia, endocarditis, and CNS infections caused by susceptible strains of",
"     <i>",
"      Staphylococcus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, neutropenia, thrombocytopenia, agranulocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Serum sickness-like reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F204174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxacillin or other penicillins or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F204155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Use with caution in neonates; elimination of drug is slow.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Oxacillin is distributed into the amniotic fluid and is detected in cord blood. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F204199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F204177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of oxacillin can be detected in breast milk. The manufacturer recommends that caution be exercised when administering oxacillin to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F204178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Bactocill in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 gm/50 mL (50 mL): $17.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 gm/50 mL (50 mL): $24.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Oxacillin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $13.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g (1): $33.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $132.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F204165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose; monitor periodic CBC, urinalysis, BUN, serum creatinine, AST and ALT",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bristopen (FR);",
"     </li>",
"     <li>",
"      Cloxacap (SG);",
"     </li>",
"     <li>",
"      Cloxcin (SG);",
"     </li>",
"     <li>",
"      Dicloxalox (PE);",
"     </li>",
"     <li>",
"      Oxacil (BR);",
"     </li>",
"     <li>",
"      Oxacilina (CO);",
"     </li>",
"     <li>",
"      Oxacillin (PL);",
"     </li>",
"     <li>",
"      Oxapen (PH);",
"     </li>",
"     <li>",
"      Oxatalis (PH);",
"     </li>",
"     <li>",
"      Penstapho (BE, IT);",
"     </li>",
"     <li>",
"      Prostafilina (VE);",
"     </li>",
"     <li>",
"      Prostaphlin (CZ, EE, HN, TW);",
"     </li>",
"     <li>",
"      Stafcil (PH);",
"     </li>",
"     <li>",
"      Staficilin-N (BR);",
"     </li>",
"     <li>",
"      Stapenor (AT);",
"     </li>",
"     <li>",
"      Syntarpen (PL);",
"     </li>",
"     <li>",
"      Wydox (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F204154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F204173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into bile, synovial and pleural fluids, bronchial secretions; also distributes to peritoneal and pericardial fluids; penetrates the blood-brain barrier only when meninges are inflamed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Children 1 week to 2 years: 0.9-1.8 hours; Adults: 23-60 minutes; prolonged in neonates and with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (small amounts as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olans RN and Weiner LB, &ldquo;Reversible Oxacillin Hepatotoxicity,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1976, 89(5):835-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/978335/pubmed\" id=\"978335\" target=\"_blank\">",
"        978335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prober CG, Stevenson DK, and Benitz WE, &ldquo;The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(2):111-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/2179837/pubmed\" id=\"2179837\" target=\"_blank\">",
"        2179837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8437/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9724 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8437=[""].join("\n");
var outline_f8_15_8437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204217\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204193\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204208\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204194\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204195\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204151\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204171\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204222\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204170\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204215\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204174\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204155\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204160\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204163\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204199\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204177\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204178\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323563\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204165\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038712\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204154\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204173\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9724\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9724|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/56/900?source=related_link\">",
"      Oxacillin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=related_link\">",
"      Oxacillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8438="EP study tracing RF ablation atrial tachycardia";
var content_f8_15_8438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Electrophysiology (EP) study tracing obtained during radiofrequency catheter ablation of atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high posterior right atrium (HRA); posterior left atrium (USER1 and USER 3); proximal, mid, and distal coronary sinus (CS9-10, CS5-6, CS1-2); and right ventricular apex (RVA) in a patient with atrial tachycardia. Radiofrequency energy application at the left atrial site of earliest atrial activation (USER1) causes initial rate acceleration, consistent with heating of an automatic focus; this is followed by abrupt termination (*) of the atrial tachycardia, resulting in a junctional rhythm. The patient had no further tachycardia during follow-up and left ventricular function returned to normal within four months of the ablation procedure, confirming that the cardiomyopathy was tachycardia induced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8438=[""].join("\n");
var outline_f8_15_8438=null;
var title_f8_15_8439="Isocarboxazid: Drug information";
var content_f8_15_8439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isocarboxazid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/34/34341?source=see_link\">",
"    see \"Isocarboxazid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Marplan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Monoamine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depression: Oral: Initial: 10 mg 2 times/day; may increase by 10 mg/day every 2-4 days to 40 mg/day by the end of the first week (divided into 2-4 doses). After first week, may increase by up to 20 mg/week to a maximum of 60 mg/day. May take 3-6 weeks to see effects. Dose should be reduced once maximum clinical effect is seen. If no response obtained within 6 weeks, additional titration is unlikely to be beneficial.",
"     <b>",
"      Note:",
"     </b>",
"     Use caution in patients on &gt;40 mg/day; experience is limited.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in severe impairment. Use with caution in mild-to-moderate impairment to avoid accumulation.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in patients with a history of liver disease or abnormal liver function tests.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Marplan&reg;: 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088633.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088633.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Dizziness (29%), headache (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (4%), palpitation (2%), syncope (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sleep disturbance (5%), drowsiness (4%), anxiety (2%), chills (2%), forgetfulness (2%), hyperactivity (2%), lethargy (2%), sedation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (9%), constipation (7%), nausea (6%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency (2%), impotence (2%), urinary hesitancy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (4%), myoclonus (2%), paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%), heavy feeling (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Akathisia, ataxia, black tongue, coma, dysuria, euphoria, hallucination, hematologic changes, incontinence, neuritis, photosensitivity, sexual disturbances, SIADH, spider telangiectases, toxic amblyopia, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypersensitivity to isocarboxazid or any component of the formulation; cardiovascular disease (including hypertension); cerebrovascular defect (suspected or confirmed); history of headache; history of hepatic disease or abnormal liver function tests; pheochromocytoma; severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Concurrent use of antihistamines, antihypertensives, bupropion, buspirone, caffeine (excessive use), CNS depressants (including ethanol and narcotics), dextromethorphan, diuretics, elective surgery requiring general anesthesia (discontinue isocarboxazid &ge;10 days prior to elective surgery), local vasoconstrictors, meperidine, MAO inhibitors or dibenzazepine derivatives (eg, amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline, doxepin, carbamazepine, cyclobenzaprine, amoxapine, maprotiline, trimipramine), SSRIs or SNRIs, spinal anesthesia (hypotension may be exaggerated), sympathomimetics (including amphetamines, cocaine, phenylephrine, pseudoephedrine) or related compounds (methyldopa, reserpine, levodopa, tryptophan), or foods high in tyramine content",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupropion: At least 14 days should elapse between MAO inhibitor discontinuation and bupropion initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buspirone: At least 10 days should elapse between isocarboxazid discontinuation and buspirone initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO inhibitors or dibenzazepine derivatives: At least 1 week should elapse between the use of another MAO inhibitor or dibenzazepine derivative and isocarboxazid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: At least 2-3 weeks should elapse between MAO inhibitor discontinuation and meperidine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SSRIs or SNRIs: At least 2 weeks should elapse between the discontinuation of sertraline or paroxetine and the initiation of isocarboxazid. At least 5 weeks should elapse between the discontinuation of fluoxetine and the initiation of isocarboxazid. At least 1 week should elapse between discontinuation of a SNRI and the initiation of isocarboxazid. At least 2 weeks should elapse between the discontinuation of isocarboxazid and the initiation of SSRIs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Isocarboxazid is FDA approved for the treatment of depression in children &ge;16 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertensive crisis: Cases of hypertensive crisis (sometimes fatal) have occurred; symptoms include severe headache, nausea/vomiting, neck stiffness/soreness, photophobia, and sweating. Monitor blood pressure closely in all patients. May occur with foods/supplements high in tyramine, tryptophan, phenylalanine, or tyrosine content; treatment with phentolamine is recommended for hypertensive crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: MAO inhibitors may mask anginal pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; sensitization to the effects of insulin may occur, monitor blood glucose closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists, especially in patients using excessive doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Isocarboxazid is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Do not use with other MAO inhibitors or antidepressants. Do not use within 5 weeks of fluoxetine discontinuation or 1 week of other antidepressant discontinuation. Avoid products containing sympathomimetic stimulants, dextromethorphan, disulfiram, and meperidine. Concurrent use with antihypertensive agents may lead to exaggeration of hypotensive effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The MAO inhibitors are effective and generally well tolerated by older patients. It is the potential interactions with tyramine-containing foods and other drugs, and their effects on blood pressure that have limited their use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperactive or agitated patients: Use with caution in patients who are hyperactive and/or hyperexcitable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Isocarboxazid is not generally considered a first-line agent for the treatment of depression; it is typically used in patients who have failed to respond to other treatments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelography: Discontinue at least 48 hours prior to myelography.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Monitor for increased effects with coadministration; caution patients about effects. Avoid beverages containing tyramine (eg, hearty red wine and beer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Kava kava, valerian, St John's wort, and SAMe may increase the risk of serotonin syndrome and/or excessive sedation. Supplements containing caffeine, tyrosine, tryptophan, or phenylalanine may increase the risk of severe side effects like hypertensive reactions or serotonin syndrome. Management: Avoid kava kava, valerian, St John's wort, SAMe, and supplements containing caffeine, tyrosine, tryptophan, or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13396763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5551133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3196160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tyramine-containing foods/beverages. Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Marplan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $346.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4794598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Liver function tests (periodic); blood pressure, heart rate; mood, suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Marplan (DK, GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thought to act by increasing endogenous concentrations of epinephrine, norepinephrine, dopamine, and serotonin through inhibition of the enzyme (monoamine oxidase) responsible for the breakdown of these neurotransmitters",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al, &ldquo;Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2006, 47(1):8-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8439/abstract-text/16384803/pubmed\" id=\"16384803\" target=\"_blank\">",
"        16384803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8439/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8439/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8439/abstract-text/10192596/pubmed\" id=\"10192596\" target=\"_blank\">",
"        10192596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Shulman KI, Tailor SA, et al, &ldquo;Tyramine Content of Previously Restricted Foods in Monoamine Oxidase Inhibitor Diets,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1996, 16(5):383-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/15/8439/abstract-text/8889911/pubmed\" id=\"8889911\" target=\"_blank\">",
"        8889911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8991 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8439=[""].join("\n");
var outline_f8_15_8439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708955\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184651\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184662\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184654\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184655\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160037\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160038\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184642\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184629\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874834\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184643\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184660\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184633\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299546\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184637\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184650\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184638\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13396763\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5551133\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3196160\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184647\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4794598\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539881\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184632\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8991\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8991|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/34/34341?source=related_link\">",
"      Isocarboxazid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8440="Overview of papillary thyroid cancer";
var content_f8_15_8440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of papillary thyroid cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8440/contributors\">",
"     R Michael Tuttle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8440/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8440/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8440/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/15/8440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Cancer Society estimated that approximately 44,670 new cases of thyroid cancer would be diagnosed in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall incidence has risen from",
"    <span class=\"nowrap\">",
"     1.3/100,000",
"    </span>",
"    for women and",
"    <span class=\"nowrap\">",
"     4.6/100,000",
"    </span>",
"    for men in the year 1935 to",
"    <span class=\"nowrap\">",
"     16.3/100,000",
"    </span>",
"    for women and",
"    <span class=\"nowrap\">",
"     5.6/100,000",
"    </span>",
"    for men in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/2\">",
"     2",
"    </a>",
"    ]. Further, the age-adjusted incidence in women increased 4.3 percent per year from 1992 through 2001, the most rapid increase among malignancies tracked by SEER [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general pathogenetic, pathologic, and prognostic features of papillary thyroid cancer and its variants will be discussed here. The treatment of well-differentiated thyroid cancers and an overview of follicular thyroid cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"     \"Overview of the management of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=see_link\">",
"     \"Overview of follicular thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of head and neck external beam radiation commonly used to treat benign childhood conditions between 1910 and 1960 led to an increased incidence of thyroid cancer in the second half of the last century [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .) However, since radiation therapy for benign childhood conditions was largely abandoned in the 1950s to 1960s, it is unlikely that the increasing incidence in thyroid cancer seen in the last 10 to 15 years is associated with childhood radiation exposure. Some authors suggest that the increase in thyroid cancer in the United States may be primarily due to an increased detection of small papillary cancers secondary to more widespread use of neck ultrasonography, and fine needle aspiration of very small thyroid nodules.",
"   </p>",
"   <p>",
"    In a report based upon the SEER database from 1973 to 2002, the incidence of papillary cancer increased from 2.7 to 7.7 per 100,000, a 2.9-fold increase (95% CI 2.6-3.2) (",
"    <a class=\"graphic graphic_figure graphicRef67859 \" href=\"UTD.htm?11/27/11699\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/5\">",
"     5",
"    </a>",
"    ]. The data were consistent with the hypothesis that the dramatic increase was largely driven by the detection of small thyroid cancers: 49 percent of the papillary thyroid cancers were less than 1 cm, and 87 percent were 2 cm or less. A second report that analyzed the SEER data from 1980 to 2005 confirmed the observation that the increasing incidence of thyroid cancer was most dramatic for small tumors, but also noted statistically significant increases in the incidence rates of tumors greater than 5 cm. Furthermore, the incidence of regional metastases and distant metastases has also increased over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/6\">",
"     6",
"    </a>",
"    ]. Neither of these studies demonstrated a significant change in the incidence of follicular, medullary, or anaplastic cancers, but these tumors are generally less often detected incidentally as microcarcinomas. Based on the current data, it appears that the rise in thyroid cancer incidence is due to medical surveillance and improved disease detection, although one cannot conclude this with absolute certainty.",
"   </p>",
"   <p>",
"    The usual female-to-male ratio of papillary thyroid cancer is about 2.5:1, with most of the female preponderance occurring during the fourth and fifth decades of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for the development of differentiated thyroid cancer is a history of radiation exposure during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/7\">",
"     7",
"    </a>",
"    ]. Potential sources of radiation exposure include medical uses of radiation (eg, treatment of childhood malignancies) or environmental exposure secondary to atomic weapons (eg,",
"    <span class=\"nowrap\">",
"     Nagasaki/Hiroshima,",
"    </span>",
"    Japan), or nuclear power plant accidents (eg, Chernobyl). In the past, ionizing radiation was used to treat a wide variety of benign conditions of the head and neck, although this practice essentially ceased in the late 1950s to early 1960s due to increased appreciation of the carcinogenic effects of radiation on the thyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=see_link\">",
"     \"Radiation-induced thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of thyroid cancer in a first-degree relative or a family history of a thyroid cancer syndrome (eg, familial polyposis, Carney Complex, multiple endocrine neoplasia type 2 [MEN2], Werner Syndrome, or Cowden syndrome) increases the risk that a nodule may be malignant. In one study, there was a 10-fold increased risk of thyroid cancer in relatives of thyroid cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/8\">",
"     8",
"    </a>",
"    ]. In a second report, the standardized incidence ratio for papillary cancer was 3.2 with an involved parent, 6.2 with an involved sibling, and 11.2 for a female with an involved sister [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of rapid growth, a thyroid nodule or fixation of the nodule to surrounding tissues, new onset hoarseness or vocal cord paralysis, or the presence of ipsilateral cervical lymphadenopathy should all raise the suspicion that a nodule may be malignant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other possible (but not proven) risk factors have been reported. Their relative importance appears to be small, but not completely defined. Potential risk factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Occupational and environmental exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatitis-C-related chronic hepatitis (odds ratio 12.2 in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased parity and late age at first pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is becoming increasingly apparent that mutations or rearrangements in the genes encoding for the proteins in the MAPK pathway are critical to the development and progression of differentiated thyroid cancer (",
"    <a class=\"graphic graphic_figure graphicRef71801 \" href=\"UTD.htm?29/33/30237\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The importance of this pathway is emphasized by the finding of exclusive, non-overlapping activation mutations in",
"    <span class=\"nowrap\">",
"     ret/PTC,",
"    </span>",
"    NTRK1, Ras, or BRAF in as many as 70 percent of well differentiated thyroid cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, thyroid targeted activation of either",
"    <span class=\"nowrap\">",
"     ret/PTC",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/17\">",
"     17",
"    </a>",
"    ] or BRAF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/18\">",
"     18",
"    </a>",
"    ] has been shown to result in development of thyroid cancer in transgenic mice.",
"   </p>",
"   <p>",
"    It appears that tumors harboring a BRAF mutation may be more aggressive with higher rates of extrathyroidal extension, lymph node metastases, and clinically apparent recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link&amp;anchor=H8#H8\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\", section on 'Papillary thyroid cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, most patients with papillary cancers presented with a palpable thyroid abnormality discovered by the patient or their health care provider.",
"   </p>",
"   <p>",
"    Today an increasing number of nonpalpable thyroid nodules are being incidentally detected on cross-sectional imaging studies of the neck done for reasons not related to the thyroid. Regardless of how they are discovered, the diagnosis of thyroid cancer is usually made by fine needle aspiration biopsy (",
"    <a class=\"graphic graphic_picture graphicRef71385 \" href=\"UTD.htm?11/21/11603\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary cancers are typically unencapsulated and may be partially cystic. Microscopically, most are characterized by the presence of papillae consisting of one or two layers of tumor cells surrounding a well-defined fibrovascular core; follicles and colloid are typically absent (",
"    <a class=\"graphic graphic_picture graphicRef81310 \" href=\"UTD.htm?1/17/1305\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The morphologic diagnosis is based upon an aggregate of typical cytologic features (",
"    <a class=\"graphic graphic_picture graphicRef71385 \" href=\"UTD.htm?11/21/11603\">",
"     picture 1",
"    </a>",
"    ), none by itself pathognomonic of papillary cancer. The nuclei are large, oval, and appear crowded and overlapping on microscopic sections. They may contain hypodense powdery chromatin, cytoplasmic pseudoinclusions due to a redundant nuclear membrane, or nuclear grooves.",
"   </p>",
"   <p>",
"    About one-half of papillary cancers contain calcified psammoma bodies, the scarred remnants of tumor papillae that presumably infarcted (",
"    <a class=\"graphic graphic_picture graphicRef72821 \" href=\"UTD.htm?4/59/5042\">",
"     picture 3",
"    </a>",
"    ). Inflammatory cells may surround or infiltrate areas of malignant growth, although this does not usually indicate the presence of chronic autoimmune thyroiditis (Hashimoto's disease).",
"   </p>",
"   <p>",
"    Papillary thyroid cancer is often multifocal. In some cases, this represents intraglandular metastases from the primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/20\">",
"     20",
"    </a>",
"    ]. However, in one study of 10 women with multifocal papillary cancer, individual tumor foci were shown to have independent clonal origins in 5 of the 10 women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/21\">",
"     21",
"    </a>",
"    ]. In a second study, discordant patterns of BRAF mutations were found in 40 percent of the multifocal papillary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of nodal metastases in adults depends upon the extent of surgery. Among patients who undergo a modified radical neck dissection, up to 80 percent have lymph node metastases; one-half have microscopic involvement only. At diagnosis, clinically detectable regional lymph node metastases are more common in children (approximately 50 percent) than adults.",
"   </p>",
"   <p>",
"    Invasion of either the thyroid capsule or a lymph node capsule into surrounding soft tissue has been reported in 5 to 35 percent of surgical specimens, whereas vascular invasion is seen in only about 5 to 10 percent.",
"   </p>",
"   <p>",
"    From 2 to 10 percent of patients have metastases beyond the neck at the time of diagnosis. Among such patients, two-thirds have pulmonary and one-fourth have skeletal metastases. Rarer sites of metastasis are the brain, kidneys, liver, and adrenals.",
"   </p>",
"   <p>",
"    The growth pattern and biologic behavior of papillary cancer are variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one end of the spectrum is the common microcarcinoma (formerly called occult papillary cancer), defined as a tumor &lt;1 cm in diameter. These microcarcinomas are found in 15 to 30 percent of thyroid glands at autopsy. This high frequency, coupled with the rarity of clinically detected papillary cancer, suggests that the presence of a single focus of microcarcinoma in a thyroidectomy specimen is likely to be an incidental finding of no clinical importance.",
"     </li>",
"     <li>",
"      At the other end of the spectrum is a large, locally invasive cancer with distant metastases noted at the time of diagnosis. These tumors are also more likely than microcarcinoma to metastasize through intrathyroidal lymphatic channels and form multifocal tumors or involve regional lymph nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with papillary cancer do not die of their disease. As an example, in one series of patients with a median follow-up of 16 years, the cancer-related mortality in patients without metastases at presentation was only 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain clinical and pathologic features have been identified that portend a somewhat higher risk for tumor recurrence and cancer-related mortality. The most important are age at diagnosis, size of the primary tumor, and the presence of soft tissue invasion or distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients diagnosed between the ages of 20 and 45 years have the best long-term prognosis, with cancer-related death occurring rarely during 30-year follow-up periods. This was illustrated in an analysis of 30,504 patients in the SEER database between 1998 and 2003, in which nodal involvement had no effect on survival for patients under age 45 years, but increased the risk of death by 46 percent in those age 45 or older [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, patients aged 45 years or older who have a lymph-node recurrence are more likely to die of their disease than those under age 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tumor size",
"    </span>",
"    &nbsp;&mdash;&nbsp;While small tumors usually have an excellent prognosis, clinically evident recurrences are not infrequently detected. A survey of 299 patients with thyroid cancers less than 1.5 cm found no deaths over a mean follow-up of 45 months, but 14.4 percent had evidence of",
"    <span class=\"nowrap\">",
"     persistent/recurrent",
"    </span>",
"    disease. Persistent or recurrent disease was associated with non-incidental cancer, lymph node metastases at presentation, or bilateral tumor, but not size (greater or less than 1 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is poorer in patients who have large tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one series, as an example, 20-year cancer-related mortality rates were 6, 16, and 50 percent for patients whose primary tumor diameters were 2 to 3.9 cm, 4 to 6.9 cm, or 7 cm or larger [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Soft tissue invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;When present, soft-tissue invasion increases the risk of death fivefold. It can also cause substantial morbidity if there is involvement of the trachea, esophagus, recurrent laryngeal nerves, or the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of survival in patients with distant metastases is variable. Among patients with small pulmonary metastases but no other metastases outside of the neck, the 10-year survival rate is 30 to 50 percent; even higher survival rates have been reported in patients whose pulmonary metastases were detected only by radioiodine imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/31\">",
"     31",
"    </a>",
"    ]. Conversely, the median survival of patients with brain metastases is only about one year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In multivariate analysis, 18 FDG positivity was the most powerful predictor of death in a large cohort of patients with metastatic disease. Patients with large volume, intense FDG uptake had a three-year disease-specific survival less than 50 percent from the time of the PET scan [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/33\">",
"     33",
"    </a>",
"    ]. This may be due in part to lower radioiodine avidity in papillary cancers demonstrating a high FDG uptake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors associated with either a minor increase in the risk of recurrence or death are multicentricity of intrathyroidal tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/34\">",
"     34",
"    </a>",
"    ], bilateral or mediastinal lymph node involvement, greater than 10 nodal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/35\">",
"     35",
"    </a>",
"    ], nodal metastases with extranodal extension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/35\">",
"     35",
"    </a>",
"    ], male sex, and delay in primary surgical therapy of more than one year after detection of a thyroid nodule. The extent of initial surgery and the use of radioiodine therapy in advanced papillary cancers are also associated with improved outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical treatment of differentiated thyroid cancer\", section on 'Choice of procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link&amp;anchor=H3#H3\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\", section on 'Treatment of residual thyroid tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the traditional histopathologic risk factors used in most of the current staging systems, later data suggest that the specific molecular signature of the tumor may be associated with clinically significant outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with the BRAF mutation (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above) are more likely to have extrathyroidal invasion, lymph node metastases, advanced stage at diagnosis, and tumor recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/36-38\">",
"       36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expression of vascular endothelial growth factor (VEGF, a potent stimulator of endothelial cell proliferation) in thyroid cancer specimens may help predict the presence of metastases. As an example, in a retrospective study of 19 patients with papillary cancer, a high level of immunostaining for VEGF correlated with a high risk of metastatic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/39\">",
"       39",
"      </a>",
"      ]. In a second report, elevated preoperative serum VEGF-C concentrations were an independent risk factor for nodal metastases and advanced tumor stages [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous prognostic scoring and staging approaches have been developed in an attempt to combine some or most of these clinicopathologic features to determine prognosis. Unfortunately, conventional staging systems with the greatest predictive value for identifying the risk of disease-related death (eg, the TNM-based approach advocated by the American Joint Committee on Cancer and the schema used by the National Thyroid Cancer Treatment Cooperative Study Registry) do not predict overall outcome well [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is primarily because young patients have a very low risk of death but a significant risk of recurrence, while older patients have an increased risk of both disease-specific mortality and recurrence. Therefore, a staging system designed to predict death is also likely to correlate with an increased risk of recurrence in older patients but will significantly underestimate the risk of recurrence in young patients.",
"   </p>",
"   <p>",
"    The American Thyroid Association (ATA) thyroid cancer management guidelines proposed a novel clinico-pathologic staging system designed to stratify patients as having either a low (papillary thyroid cancer confined to thyroid), intermediate (regional metastases, worrisome histologies, extrathyroidal extension, or vascular invasion), or high (gross extrathyroidal extension, or distant metastases) risk of recurrence (",
"    <a class=\"graphic graphic_table graphicRef52272 \" href=\"UTD.htm?36/2/36908\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/42\">",
"     42",
"    </a>",
"    ]. These initial risk estimates for recurrence are then modified on the basis of additional data (including response to therapy) obtained during follow-up for each individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/43\">",
"     43",
"    </a>",
"    ]. This dynamic risk assessment approach allows for more accurate risk assessments than either a static estimate of risk based on the TNM staging system or the ATA risk of recurrence classification system.",
"   </p>",
"   <p>",
"    We currently recommend using both the TNM classification scheme for prediction of disease-specific mortality and the ATA risk of recurrence staging system for initial risk assessment. These initial risk assessments are then actively modified based on data obtained during follow-up that reflect the individualized patient&rsquo;s response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/25,43\">",
"     25,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=see_link\">",
"     \"Clinicopathologic staging of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VARIANT FORMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Follicular variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the several histologic subtypes of papillary carcinoma, the follicular variant is probably the most common, accounting for about 10 percent of all papillary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/44\">",
"     44",
"    </a>",
"    ]. In the past, these tumors were mistakenly called follicular adenomas or cancers because of the near total or total absence of papillae; a similar error can be made on the basis of fine needle aspiration biopsy.",
"   </p>",
"   <p>",
"    These tumors are characterized by small to medium-sized follicles, typical of follicular tumors. Cytologically, however, they display the typical features of common-type papillary cancers, including large overlapping nuclei with hypodense chromatin, nuclear pseudoinclusions, and nuclear grooves; most also contain psammoma bodies (",
"    <a class=\"graphic graphic_picture graphicRef72821 \" href=\"UTD.htm?4/59/5042\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follicular-variant papillary cancers tend to be smaller than common-type papillary cancers, and the risk of regional lymph node metastases may be lower. However, the overall rates of recurrence and survival in patients with these tumors are very similar to those of patients with common-type papillary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Tall-cell variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tall-cell variant form of papillary cancer is a more aggressive tumor than common-type papillary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. These tumors account for approximately 1 percent of papillary cancers. They are characterized by tumor cells with eosinophilic cytoplasm that are twice as tall as they are wide. The primary tumors tend to be large, they are often invasive, and many patients have both local and distant metastases at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/46\">",
"     46",
"    </a>",
"    ]. Most patients have evidence of disease after initial therapy, and the five-year mortality rate is higher than in patients with common-type papillary cancers.",
"   </p>",
"   <p>",
"    In one study of 62 patients with the tall-cell variant of papillary cancer without extrathyroidal extension at presentation, prognosis was still worse compared with classic papillary cancer: 6.4 percent developed distant metastases versus none of the patients in a comparison group with classic papillary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8440/abstract/48\">",
"     48",
"    </a>",
"    ]. However, among patients without initial lymph node metastases or extrathyroidal invasion, no one developed metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other variant types of papillary cancer have been described, also based upon histologic differences from common-type papillary cancers but considered to be papillary cancers because of the characteristics of the tumor cell nuclei:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The insular variant of papillary cancer is characterized histologically by solid nests of tumor often separated by fibrous bands, but the tumor-cell nuclei have the same characteristics as do the nuclei of common-type papillary cancers",
"     </li>",
"     <li>",
"      The columnar variant, which consists of elongated cells with palisading nuclei",
"     </li>",
"     <li>",
"      The H&uuml;rthle or",
"      <strong>",
"       oxyphilic",
"      </strong>",
"      variant, which has cellular features of H&uuml;rthle-cell carcinomas but cells that are arranged in papillary formations",
"     </li>",
"     <li>",
"      The solid or",
"      <strong>",
"       trabecular",
"      </strong>",
"      variant",
"     </li>",
"     <li>",
"      The clear-cell variant, which must be distinguished from clear-cell carcinomas of other organs such as the kidney or colon that have metastasized to the thyroid",
"     </li>",
"     <li>",
"      The diffuse sclerosing variant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These variants are all rare and, therefore, little information about their characteristics is available. In general, however, they are thought to be more aggressive than common-type papillary cancers. As a result, patients with these tumors are usually treated more aggressively than are those with common-type papillary cancer of the same stage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=see_link\">",
"     \"Surgical treatment of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/10/36002?source=see_link\">",
"       \"Patient information: Thyroid cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dramatic increase in incidence of papillary thyroid cancer in the United States appears to be due primarily to an increased detection of small papillary cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for papillary thyroid cancer include a history of radiation exposure during childhood, a history of thyroid cancer in a first-degree relative, or a family history of a thyroid cancer syndrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations or rearrangements in the genes encoding for the proteins in the MAPK pathway are critical to the development and progression of differentiated thyroid cancer. Mutations in",
"      <span class=\"nowrap\">",
"       ret/PTC,",
"      </span>",
"      NTRK1, Ras, or BRAF occur in as many as 70 percent of well differentiated thyroid cancers. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with papillary cancer do not die of their disease.",
"      <br/>",
"      <br/>",
"      Clinical and pathologic features associated with a somewhat higher risk for tumor recurrence and cancer-related mortality include older age at diagnosis (&ge;45 years), size of primary tumor, and the presence of soft tissue invasion or distant metastases. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognostic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Variant forms of papillary cancer include the follicular variant (about 10 percent of papillary cancers) and the tall-cell variant (a more aggressive tumor accounting for about 1 percent of papillary cancers). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Variant forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of differentiated thyroid cancer, including papillary thyroid cancer, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link\">",
"       \"Overview of the management of differentiated thyroid cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     The American Cancer Society. Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2010. file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026210.pdf (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     National Cancer Institute. SEER Stat Fact Sheets: Thyroid. file://seer.cancer.gov/statfacts/html/thyro.html (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     National Cancer Institute. SEER Cancer Statistics Review, 1975-2002 file://www.seer.cancer.gov/csr/1975_2002/ (Accessed on July 25, 2012).",
"    </li>",
"    <li>",
"     Mack WJ, Preston-Martin S. Epidemiology of thyroid cancer. In: Thyroid Cancer, Fagin JA (Ed), Kluwer Academic Publishers, Boston 1998. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/5\">",
"      Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/6\">",
"      Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/7\">",
"      Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 2005; 1:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/8\">",
"      Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001; 86:5307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/9\">",
"      Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005; 90:5747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/10\">",
"      Nagataki S, Nystr&ouml;m E. Epidemiology and primary prevention of thyroid cancer. Thyroid 2002; 12:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/11\">",
"      Boice JD Jr, Lubin JH. Occupational and environmental radiation and cancer. Cancer Causes Control 1997; 8:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/12\">",
"      Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/13\">",
"      Rossing MA, Voigt LF, Wicklund KG, Daling JR. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 2000; 151:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/14\">",
"      Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004; 183:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/15\">",
"      Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/16\">",
"      Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/17\">",
"      Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996; 137:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/18\">",
"      Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65:4238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/19\">",
"      Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/20\">",
"      McCarthy RP, Wang M, Jones TD, et al. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res 2006; 12:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/21\">",
"      Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/22\">",
"      Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92:3511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/23\">",
"      Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/24\">",
"      Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/25\">",
"      Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008; 14:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/26\">",
"      Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/27\">",
"      Voutilainen PE, Multanen MM, Lepp&auml;niemi AK, et al. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001; 11:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/28\">",
"      Pellegriti G, Scollo C, Lumera G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004; 89:3713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/29\">",
"      Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/30\">",
"      Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/31\">",
"      Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/32\">",
"      Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/33\">",
"      Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/34\">",
"      Lin JD, Chao TC, Hsueh C, Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol 2009; 16:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/35\">",
"      Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005; 90:5723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/36\">",
"      Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90:6373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/37\">",
"      Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/38\">",
"      Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/39\">",
"      Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/40\">",
"      Yu XM, Lo CY, Lam AK, et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg 2008; 247:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/41\">",
"      Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/42\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/43\">",
"      Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010; 20:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/44\">",
"      Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 1994; 73:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/45\">",
"      Zidan J, Karen D, Stein M, et al. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 97:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/46\">",
"      Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol 1988; 12:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/47\">",
"      Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid 2008; 18:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8440/abstract/48\">",
"      Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid 2007; 17:655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7860 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8440=[""].join("\n");
var outline_f8_15_8440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathologic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSTIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tumor size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Soft tissue invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Distant metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VARIANT FORMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Follicular variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Tall-cell variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7860|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/27/11699\" title=\"figure 1\">",
"      SEER age adjusted rates thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/33/30237\" title=\"figure 2\">",
"      MAP kinase signal cascade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7860|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/21/11603\" title=\"picture 1\">",
"      Papillary thyroid cancer FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/17/1305\" title=\"picture 2\">",
"      Papillary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/59/5042\" title=\"picture 3\">",
"      Psammoma body FNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7860|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/2/36908\" title=\"table 1\">",
"      Initial ATA risk of recurrence classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14599?source=related_link\">",
"      Clinicopathologic staging of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21688?source=related_link\">",
"      Overview of follicular thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/10/36002?source=related_link\">",
"      Patient information: Thyroid cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1818?source=related_link\">",
"      Radiation-induced thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41064?source=related_link\">",
"      Surgical treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8441="AIDS related KS skin";
var content_f8_15_8441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75375%7EONC%2F79013%7EONC%2F69203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75375%7EONC%2F79013%7EONC%2F69203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAaIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzP7NHtypc/ieaUW8fYuffJpWkIO08A+/WhpM4GSR9a67JFDJLOEjgyYPbNV5NIilXIlkB+vSrSscgkk/pmnK+cY57UuVMGYF/4euSM2lw5zyBurn73T9YtRkmRl9VNejRnOTgcY79akLK6YZc49aPZJiseSnUdRtyVaWVTnOD2qVfEWorjFw3HvXpNxZWc/3oIyR7dKyrzw3ps+SsfluR2rOUWgOfs/Gd9Co8xi5FbNr46Yr+869M96hfwZAf9W7KPc5rNufB9wjERPuAHHuaac1sB1Efi+2Kjc2D/vVah8VWbjBkIHXr0rzyXw3qKZIjyO2DVSTSr6I4ML9M8VXtZIdz1QeJbNiQsvt1pw8Q2ZJxcAsPevJGtLuM4aKQE0w29yvJjkHfoaarSC56/wD8JHZ7f9ecg1C3iWywB55A7815L5Vxtzskxj0NILe4bgRSH8DSdaQj1WXxfZxf8tM496z7jxrbrhoyc+mc4rz1LG6kOFhfPpirEWjXshA8rb7ntS9tMPkehaR8QFimfg5xxx1qt4k8f3E4CR5Bxgiszw14NnupGeZwFHTHf3qzr3g1LfaRMR6tVOdRrUpXtoYUvi3UG4D8VAfE2oE58w+vWr6eG4APmkY/jT/7AslYkuxUe9Z+8yTJPiLUCT+9IHpUba7qDZzOeeuO9bLaNZcnLMSePeoDpFoqhssRik+buFjIOr3p/wCW7Ux9TvGOTO/51pS6dbAkKCOODmmS2loijAzgcnNTqFjPOo3Zzmd+femm/uieZ3/OrbwWoOVGQOwNV5Et1IA3D8aNRWGC/uQc+c/5003c5zmZ+feo9qBc5+gplJ3CxL9pm5/eNz70faJd2fMb86iGM89PakpXYrIl86Xn94350nnSf32/Oo6KLsLIl86XvI350GaT/no351FRRdhZFuASyAs0rLGOpya0Yb5Y1RY923PXPLVkCSTZtBO0dqaQxxmnzDSN2TVCOEJz0yaibUPvKWLMeM5rGwfyoKmnzjsa0morwFLbT1yarSXZbcwc5xjBNUwhPQUjDBpcwnEtLdkAgliO3NC3jqeCTxjrVSijmFYsPdSMPvNn6037RKMgsTUSsUdWHDA5FOmleaVpJTudjkn1NHMwshfPk/vt+dNMshPLt+dJj5c4/GkII6ildjsO8x/7zfnSiaTB+Y81HRRdisSCR/7zfnTlkl7Mx/GmxrnnGQDzV1IB5RZehHT1qXOxcYXKnnTDjzGoqf7DN6UUe0Xcr2T7Hpq5JxtyOeKe8bcAD8KiGcEhjnrS+Y20ZJz64rrJJAj7vX2p3luBhSOaZGxOMnmniUkYJOO+aegiSPIYjt7GpFJ4HY9TjvVKN8nnoO+aeswz6kdu1HMBfbg5BHA61XZwH+9z9KiNwn3myDnmo2kVsAZJ+vWpnK4F+CYDueOPrQ027eoHGMcmqiyDb83IHQVGZME7SfcCmpAWmlG0gDPqKrySDPTAx3qAygHJ65zgmo5Z+TlfxocrgS/IW3GNenIxUciRkDCrk+3Aqv5w/i5qPzhnlunQ560rjLPlwltuxR6U3am/7i/WqqzqXJZsnPTNQPdYYjpjtUtgX1dAx4UHp0qPzgJfvAHHTtWXLfpuYE8juDVM6i/JOCeg96TYz0Lw1PiMjPzMc1D4qnDGMZLY54OMVk6BchIBIXVc/KRnmqPirUMAAE5HTmqc7qwLYjluUVVBOCepB71Wa8QLkH2zmuclvmdsgZ59ai+1SOx6fN2x0qGw0N6a+2nYMnH8Rqq9+HydwBAzycc1li5DRSq65Zl4OcYOetVySw56Cp5hXL8t+7FWyMgVXe5dhnJH41XUjnJI4ptLmFckd8sSuRmmEk9aKACelJsQlLU8UDc70Y8cfWp0sWIzzn0qWy1Bso9acoBU9c9uK04rDrkZIqf7DgHaRuxjFLmRaovqYqozHAFSLAxYDBOa1FtAkm5ug4AFWo4ELrg59hScyo0kY8dmzNjqD37UwQ9QAS9dKlsqMPkLZ9D2pk1suC5j2legHep9oX7JGNFbZ29ieeeKV7TJHI5960fKIKqwIQ85IqxLbp5ZIAI459KXPYfIZ82lpFKipPFOjKGLRnoT2P0qGSy27QMAHr7VqNbiNf3QAU4y7dR7VM1rDPFCRM4cnDfLScwUDFWzCsykDHbBpFsRLIxVcBa2Psvyqm3Pqw9O1WobJhCioAzNw2ecUnUsUqdzm5LMbiFG1uw9ajNmyTKGUEkZxXTtYBwUCfMpDYB5oEC7pH2lSDtJHbikqvQHSOTvIWjVDI2WPA+lVK6DWLPMe6MMQvPtisTyX2qwRthOAccZraMk0c1SNnoS2kDSsoXqTgfWuiTw6q26OwaRmGW2/dX8ap6b5djKhlbdJkEjqMfWugn8Q2sCN9lgCswzktnB9cVlNyb903pxilqYGsabHCiudkZOFEUfUe5rnz1xWvqGoPeNIxPzMdx4/OqNvbtLKgKMd3OAOcVpFtL3jGaTfujYBM+2Nc7Ad2D0+v6V1NnpyvFGWUqH7k1LaaYSbd5FG1B16YHvW3dRKIUJcPleFUdK56lW+x0UqVlqYhhjUkb5OOODRVg2ig/MGz3+eiouVyyNdplSRhjnPQn0phnbBB/DiqUkhLsMYOTS+YOVJ7c+tevc4i6ZsEnABPGcUjSk8enU1UWRieOnqaPMKkbcfiaBFxn6BMcj1okYrtII6VTEuCSCfU015gcDcRzSYFp3+Y+uOaieTkY9O9QGfZ1Xn0qCaYEgjqP0qZAaW/KLk8g5waieRkOFPPr7VWEo465J59qqzXaKxJ4oTAvmcn7x/EVC843jJ6isq5vto+XlSPpxWfPe7ERS5bPOc0XA3prsKMHqelVhdIox1965+W9d889eevSopLpyNobilcehtyXe1ydwwfftWe96QCA2fQk1ms7McsSSabzSchXLdxcs4AB4AqF5mbv2xxUQpQpIJ9O1TcV2zZ0jUhAkgkABxwap6nePdTkhjsAx1/WqseRnnoKmRBIyPKHIP3u1FyrNorDmpJNiY8ssTgEkjGD3q1awYkJaNXHIwx46dfw61JLZRscwk4AGAeSx70rlKmykyFbZSr53HLKB93HTP5mo2HoDWqti0kfPOOAM9TT009d21s/gPzqeZFeyMlImfoOasx2ZCkyA5424rbt7QRxhvlU/7XarsdikiF2zzwPSodSxpGgjBg0xpEErDC+gFWUsk4QklR0471vx2e1EETncP4atRWcqwMZFTGf1rN1TaNDokc+lidmWwFHr1FWxZqoRlJZD7VoeSPMMcibh19ianWFnmjj2/IR94dhUubNFSMuGyUuQCC/c+lMFoPNKEjHUD0rUvAIGUxxkI36VnuqAkuzKCckg8rQpN6ilFLQQ2x28gMB0YelNjTK42hX5A4pxnSAELIGwegbNUbi9jO4Z2t6/0oSbJbijREAUqzNuAGDSNNGyYRScnof51mHUSAFJyPerUUolCBgqkEc+1HK+oKS2RegQkukwUk47dKURBZ/3QQxdMe9IV2EsuSx+Yj1rRttLIhZ3ALKScZ4rOUram0IOWi6FYRMwzOqkdc4zim/ZC0rmHKc5GeB0rorWxkDbyY8MQAOwHvUlzB5skkcADOqjbjnOeay9pZnR7BWuzFtrVPL8tmLEjJKjGKuWsElvanNvhihbdnqKu6dpzuxMgIkckMg4Ax71oRpuEsbBifLyp65A7VnKprY0hRVr7HPw25mRmiOGbLvt6bfSq32F40w7EoD0Uc5NdF9jSNHkt18tVTEue2T/AJ4qKSDBMe/jBbD8DjmqU9dCJUtNTgddQxrJDGwZS3JWohYXFtC8c58tpY94jYfKeeorqPEulvcWiamiJFG7YManJb8Krro91qNmBLEWEKgjeTlEzya7Izsjy5wfM0kccLKZiyrLkg445zUyaBdSzLGqM8hBb6Cu2s9Jt4xzFucsMNzkL6/U10cNpb2073MJLAHaqkZ5x0z3xUSrtbGlPDuW55sPD8kcsECHfK4w5XoBWxb6TKskDug3g+WCB2/xrqFtJPt7ADEhU4B/U1oR2pS8JGB5SEnI9axlXZ0U8Kt2c8ts7WXmFFj2HqR1J7Uj27RXadBGUwBn9a6aa3M9tDHhV2qxdQO3ashYg9xC8j/MTsxjO0Vip3OmVNLQqi4sEG026krwSe9FOmt5mmkIR8Fifuiii8f6Yve7GA8ijlsHtTGdQcEg5I/Oqcl5HuHQk1UlvV3DJ5+te9c8E1fMUNj5fWoHceaTuwfesuTUEDbicjtVKbUuuOW680XA32mwpy4PtUT3K7QwPTqOlc62oHOcVCb1y2SMjPTNK4jo2vcqSGDHGcVn3N8WfYc4HJrHM7bcAkfjUZOSTUthe2xrrqTBflbtzmqs94WLbT1HWqIxkZ6d6U5HXI4ouFyR53bGWJx0qImnYznbwD60+KIyuqKRk+vApXCzZFzTijDbkfeGR9Kuwworsr/OnRsDp9KlS2G4MVBBG5AT90Z6GlcpU2Z8KkOrFA4z9096lFszHIX1OPStRdPJQFgiAjd7GrNvZr8oIJBHbsKlyRqqVjKW0VxFhsZ+9wfl5qdtNfz5UHzbOAV5BHrWmsQGFjGTngY6VPBDNMSU+VF7A9anmLVNGP8A2e2xTtAJzweePXNTwWbM21thXOCQcj6iti2s3YmNgGYvgNnkitMaaYpxHlSRxntntUOokaxoyeqRzkFoGz6g4B6d6uW9quXUxkKehI5+tbMdk6uSu0sxxhhjP0p8FpJ5jpjLjnnp+FQ6iNFQZli2h8sEcFeSKnW285PkdEYjrjrWjbWCTykOAzkFmH92rkNu0V2mYB5S+vfgVnKolp1NqdFvVrQx0s42kRDy6jJG2rht4VeN2lVI1XK7e9aTQrJcyIYtqkYLdifTNLDpsjlkkC7FICk9FrJ1O5uqPZGb5QVPM3AAgnA60yFXAUkl4/rWitqVaRJSGGCEGP505bVQqq0bcDr0FHOgdOxlB02bWRhtz8/rUeJAWCsETGSetaEkByiFME88elWFtY4IRJ5kYVjlY85J/wDrCrTXQykmjn7yWWGEmTDx4AIP+etYl9fPcu/kxKo6bc4Aqxrt3JK7KJiyg9G4/H61T0q0e6ldHiHlsM564NdEYpK7OKbcpWRWeN0QCNhJOxw2wZC/j3NRPYXMpO8YI6GvUtD8J2Fvovn6pmKdzmMknkY4AXrk+vSsxP8ARWeE6fDImeGkzvx6Zpe11sjRYWTV2efDS5y2JMoACSzdB9avaTL/AAOu44G314rsdQ0QXFvNc2Z8tAQPIkf5hn36EVgrpH2d42jkaZfLEpaJeF5wQfpnrVc3MjCcHTlY1NPyUeR4htfhT6Guj0i0aQRiRCyZ2hugJPv/ACqpoumvfW8IjVgpbaWHr2rrtOgMK28cpDMZNpQfw455rhqvoenhlomzLg0/cTD5TbFOd3QgZ6EVbtbSNbiZbYEOVUrL6DPNa0EohupQYzdRsCTKcAjPp61bWNP7Pj8obZnwpX0GOlc7vudWl7GAkUQkkdZWk3Es+0dB6+1XVtoYrNIJmTzXI+YZyARkZParux4LhbRkVppCN7R9wPT+nrTNVmjWYxRosnmMq5X+EDrg/wCeaVug7metnAyXCDzA0gURKP4mHf8A+tULWMlwoguYwnzFpi5zkfT6449a1kuraC+M8cZY78RKOu4DqfaqevyLcacZm3rNgRHy1+83qTVK+hErWZnppoaGXcuU2jylP3gTx+VTLZSEmKaR0jIKEouGGOgP49amsonNtDLDLgnbENx5Q+orQmtfIu43kucDaSXPJbB6fjzV8z2J5FuYkVmYruKCMq8JDNnGCQDjJ9s1LIHTVBL5CPbxvjYBjcSOSBU8DRyzyTrIvP7uP0CA8/rUVq7LAWI8yTzPkJ6Lk4OaV9QUVYlSKJwbzkGFAFTpnnnPelBzps7hd/mkK2T3PXBqO1BltSkYZpk3E54yQe9SNJvtEUo5MuQAvRWHU1I7rcoXRJsS4fBRWXHUsM/drOuN1rGnljEzneyjngdPxq1cSFCsch2xquWPRs9sVXnmnntmmKgLxEsgXGRVxXUyqO+hC2rJuO6NN2ecgUVRazTccqSc+1Fa+4Y81XueUPeOzs2SM9s1EZZH6ZJ9RXVLaWKFh5K7gcjIpXmhjDCNUC/7tezyvueLqcskM7r8sbEY9KctlOzY2EVr3GqBSVGM4GPb2qhPftk+W3vmlZdQsQGxlXG/aM9s1CYwGALDr2qS4u5J2yxwcY4qEbPLbOd+Rj096nQWgjAAkAg+9JS4yeKmSAseOOM1NxqLZCASeKsw22/BfIBOB9a0rGxBUZK7sg5NXJrQQbQSH3dTjpmoclsbxpdWZUUCl9uAOenoPrV6OzihlcApIQRgqeDV9LeGPJVBuIwATVoW0Xm7l4crioczZUzOisgcYBMjc+2KRLMIQTjLYAya0wrL+7jUuwIAzxk1JHp2VPmtulJ+Xd2qeexap32KzCPZ5Y2MwGRnkCrVk4LFZWTcB021ftbRPmL8IFzwPmODVizs7adiRG4znAA7VnKaN4UZNmfb2bRHc4Dlm7HoK0bexI2gBUDAnGO+a0rewiVkIiztGeT19qnSJZLgidUUHoSelYOrfY6o4blWpnR2SxgvG0e5Rglu3NOhs2uSzM5jUD5mx96tK3tFnlKxBFTqMdK1FtDDb4lVC5J4UVlKq0bqgnp0MpNLEmw26qdp5J6kVMISm9liOQMHHr/+qtGGCHyV8mTywORjkn2FKUkYgFlXJ2gquQB3JNZ8zZsoRiZ0dgXcyW7iNzwwIyB71ZOnstvt8zMpG4k8cZrQis4ym7ziI1BZj/eHqaka08uwlkVWkz0Y9yannY+VIxzYNskV2+6eSP51Zs9OWW0Zi7HJ4zWnZWDJGVkdsvw7Nz+FPjtWy6bhtX5sDrQ5CSSRzMyuzLEkQIB2s3U9eTS3aSx7YpkHBGB7ds1rLbsCjKcjGUwPfkn3ptzal76YKGCso2ZXAJJxWsbsynoYl3LBHuD5EhG3K9s+tc3qDiMOoJIBAbHUewrttdtUCxxIHIDbX6bcjtnvXPW+nSXd1KI48biOG5yK6qSPOxE2chBpU15PIoX92q792eeTxXoHh3wv9ktBJdoyKpA3AYyevSul8JeFrS41C3vU82S3ij/e71CjzM4wtb2v3MOsmW3s4xgOFWR87mYcfKOnHvxWlS/KLC0veu0cxlbvZLJMGbO0CQ4II7Aeg7+tV/7FjubuQ7lMRViXRDhmHYE+tdXYaSbdmhdLd5mAKzzxg7COq8dPrXRTWFzNcpJdiBhjCR5wrN1GPbj9ayhSctTsq1YpWR5wln5uj26fYmlvWJV0f7m3HG31P41WGhwPZKsEKC9fo0asjAfxKy9MZB5r0O4Fn9hE9xCGaU7GiQcRsDg7j64/XFULSdY9bSLO+KIlNgGSUIHf19a6HFQjY4rOpLmZQ8NaFaJZKIXLTRuSuG24I6qR784qzp4CZnwUL3BQsyZO3AAA9SOc06W4+zWEErSOiTb87VG7IY8e9MsQgtZZxNvfkyws20DOMEY6HPeuKpq9DsgrLUq3iRxuyp5ht3k8lDx8q55JP9al1JTbCabLlYZFWNOMqT1z9aZE4SAvcbAszCNSQcYB6gev86Y1y1zHIBKq4cyT7l4Yr0H6D86xWxprcRXb7YnzMpiAZN4wQB2x9O3vURkUmSd2SHy8ldq5U5PTHpVmISTyrNJCScuWCclRjnNUgyTRxW0o2LvJdcYJHvU7aMvclubFE09J1kUQjJITknkZ5pePs07FC9sV2qQMbTxnPvUcqrFBHLC4EHmBFB6emStNZo7ODyfMZYRudRtwWPYZ9OtC7Im76leydXOS20RsE5I2478Vfs2tbi8dNyOGTac9SRmsiPC23n+XuJJYYPQHjHvVi3hNs8LbSs0GNw/iJJzjH6VSSE3oLblLeN2ZfLCNsBK55z83061bWMCzR0YEu5OxSBhV7/j6d6gM5YyLdRMi7wHYrjg9ePXFOuHGSYEAjkUhTjnavQ0rdRp3KQuj8yRAKZSFTI525J59elU0uXkeIF41EauJCuTgdfzzVouC37kKGCZMrc/lVKzghaPareWzZLgNgt9KtGb00JfOjuuWKb3IUBxgYHqfU1UZ1aZlc4iD7go/p7U5/LhW7QkbBtRBjk5FVp7jEKLMpPATp29KaXYzb6iy3F28rsqJtLEj5KKUtydqyAdgZOaKnlfYvmR45JqbfOFyc9GzVNriRurH3561GELHAp/kPkcYB717bkfOpNkbMSST1NABNXI7J2/keKnjtwWUbMt6dBUcxoqTe5nLGxPSrX2RkALD0P4VqxWy7tpwF3ct1OKtNbLKxZ3BWNMADgke9JzNFSSMqG3XDYXJHGMVdtrRlzlACRwew96sxQBLhXK44yOe1XNq3BDBvmHKjtUORrGBVhtyQgiw0i/e4xVh4ncneobBBwf61fSHYFYyDJyMAdaiRolZV2Pjd82OSTWd2zVRtuLBawu5dlYt04qe0tB9pZZjhidwHXipfKltxAy/K7n5cjr+FdHZWUbKwcqXwAdvNZTqcqOmnRUnYwJNOWR2aGXLAjkjGBnqKs/ZhHLuIM7LgHHT61trpwhiAZGZWBLAcBcdOait4BO7RxwOFXO89AQKy9pfY3VBR3EEdsELLsDY6LzQLG5HzwsDxnBHFTLZwuuISkTBgpI7fQfzrb0qxzFHJHI+Y87lI4Y5xis3K2pvGPcwrVJJoZ4xKAyDJbGMewqSCyEiqxXeOGOQf1rdji/1qPBli2RgZ+n41aNrPNABGNqg4KgdCPSs3O2xry9zEjRftaoqPsPDY4WtSBIbrbGyvu5O/wDH+dWFsAbQyyXHlgAbs+oGfyzTrGOVXORukdSdoHAHrU3uNu2xSa2VZPJtI1lABOBxtGev0qZLSSRQghyoUEqoyDzj8utWILd1KP8A89G5OPwwa17aGayvvMiIGx9m1x278e1NdiJTtsZr2ojHltA0YnwASOh6Y49qsoltcSR2kDrEkTgK7Z5AHzD354rdli8+8tjIhIbc4iXqxAwCKzLNVLzRBI1lZQnzf8sjnnn8a0jDuZOd1cothRtnGFMysNo+XHOc1Zlsg0s0luzKjyBVJHBPv+HIqzMJ4LSCXYPs8Mwgyy8yA5+Yj6dK2dRjS50xmtMwL545JADYPOPerjR5tTOdbl2ObuNOaGQmWMsGYwA524c4xinanbsumzTxfKqOIlUDmRgQMA/0q3qVvPFFbBZ2luZrhpYlflQFBOPesLUr+++y2zzRktE3mmMcBucgt79enatowSdmZym7XKOvWXmwmaIOqqwEuQTt9/6V1fhjwe0U0NxLtki4kwWxu4GOnb+ddToGn2n9hKyhWiuEMkpC5LFhyB7Vs6fBDBEYYMBYSIwAc4wBwfeu6FJQ3PNq1ubYy7TTBDaSW8yIIjnAiAXcPQ/nisW20K9t1mIWFIZOHA52gdNo74rsJCNzgpuK4HHuKxrWG4BuWvPNDQOTGd2VZTj88HNE4KTQ6VaaTMdIk06RVUNMFOTkZPTg/wCelRXNzcSOGnTy4oXBLY4G7A5/OtyOWGK2e6vz5ZMrjc3QAdBXN63fyXlw8dhLHM2fKEaLjzGzx19ByaLKnHQ053UepTluZkvJNPcKbOHHnyIco57AfXOavCxtILxsuWaXrIvVRwAc+2Kpi2aC7gjv4w0rzhiVPy5Xtmrah5dYneJlSKOIAAdFJbsPpnmuWc02r7nRGLsU7xmDW1jJDGv74rGxOVwO5PqRzmqmrwCMvLaKWkiOwgttDqQM/wCfSp9RvFu7lIYY2Ece0NMRwqk+nvRcRQIzPGySwEGEFs8dh+uBXJLXU6I3W5BBIJY2bydq5OP3fVicjA7dKzGhayvC19Krwu5L5GQCxyGI6nitPUpJUlR4GMYVVWVWHyhuh57nFZk11K9201xCzhPnz/eHYfXpUX10KSbCS6YRvBGzrLl/lY4C4ORux36U+KQ3I86O3j/djeIycEkgZ56n1qDSJBPJcLJFK0z/ACjA6LnJqwzS2sEhmIwVC7M8gZ4/XFDfQpIZaW0WoB9sieXuzgnlSfaq0m+OMpKzFUDIzcZCk8das2Bjigji3eW+zZuwPXJz6detRbWbVJWiXzLWFSwZ/u7gOfr1pJfcDb6lK4ZrTU9u4eRuV0jYfMcdCf8ACm6nJP8A2g9zbFm3OCTjGSB/SoXiaa4nlc5U4Hy9QT6e+BnFR2txcyWTJGVEcXzN5n3mPYYrVeRk9NGbk5dZUMzf6xM/NhtoI5z9Ko3LFmdZJDHEGCgkYyo71UeWe1t3md0ztB8oDcfTJPaoJZJJrCOMuylhu5PG09RUcvUfP0RK7ia0KQkRxSysd2OR7fjVGR4owil2Xy1IJXBOfap3AkuysAUBF2og+6fXHv61Uk2JMIVK7VUuzMOuO1UkkZSbE8plMzKVK9QznoD/AJxT9QRhLbG3dSY0DkjBx7fWmJG1xKdis4Zd5XPT6+lV7ORozIoiAwdwfONo9BVW6ktpKxIZrgkk28TH1I5NFG+EcGVSe53UUa9h3ff8Ty2G0CnccEjgYPSrkdk0rAONqY4J6/XFWoraSFw8BUMx+XPIqzFGDI/zsZByxNd7kcEYEMFrFHKAQ7sCevAzU39nIUaXIz6tx+lWBAQqsG2ofXvVqRFLRB49249jwKzbfQ1UO5Ta1WGFcxgk8nB5oFuhiJVSMcEVox20zSb2LBicbPSrYgWNim0uc8gDrUOZqqVzNtbJ/IVgu4kcAirrxshSGSLDFfmZVAGOwrQEcXkLIGZMsAR3B9KtNaQsdyZfoevJrJ1NTohQVtDFESeapZfKjHUnn/P1qxAsbKJPs6GQsACRgceprd8g3BEUkCkIMEdMelZ1xZyeYqqu5UONgPymkql9CnS5dSa2t4XmSe6ZSdpC4PAHqKuT2yWzCdQvODluDg96rJbobVZIsA4BUYzhvat0WJ/sfzpWR1+XejcvWUnqbwWmxTZv3DmQuwfHOTgfXH6Vct4JPICIqLGBzjgscVH5kMjFCfJjUZGw4BPU1ri3jukVlDZH3NvGOOtZt2RqnrqYa26A/Lgb5CASvykD0/HrW5Ev2Q7AuLdkIyejEdx681btbGSDysqBb79pUn5ix9B6ehq3NZebFCANiNhQSxG1em4H0/rQ23oK6RVtbaX94TMFDBcttB2tjIAParweF7QSI5doTukRMKf9ofXHSnf2farbW6xTbX8wFkBwAO1K8Sx3V3bSQ/Z40yQNud30/OnyXZk530KlhBZXcBiDbyy7grcFAc4/HpV7T41El4Y/uJAuJH7Dv7nmp4UYaVDICFkMPLBeRgcH9KmtEdrIz+XIjCMRMzfxNnrWih73oZyqaeoWumsILeBEWKYlVwfZs5+p/WpTYT7Lm1mAa4kdVUhsAgknI/DrVrULmNLuC1eJwY41fzgenoSO9VZL2C6mgluEYIZFDsuQy4zgD2PWtHGK0ZjGU3qTJ9otvEFv9oRZFjVnjYHA4GAP89Kz5ZrGTUre5XezXW4M3Qgqc5x+WDVyfUFaaObm4TyZIpm28R5PBH6fWraz21veSyz4WBwke5RzGSBkEfhVRsF5LW3QhnfztNsSGV2MxaTPHbAz6dRVTTD9pi3TvFGbVHtzGVOCzE/N9eelaDyothHMqFIxMVMP95SeSf0Oahs4pIHu5GX7TNNcFZG/hGAduPQ8da0jbmIcvdHXYWzu7ZeptYQpYjIRiuM5qJtKJ043N8QFYLC6A/wHvnse2aotcvdO7RwSLKrncCuAXx/FUmpatJBp0ljbK8sTwCSMqM7s9T7DPatI2ldsiUZRSSN7wRdI1rcW3nK8cchEK8ZRR2J71ruiwsy267HdizMvJJJrznwzdT2YtpXtliVvMYtv+V8gYH1z+td/bapbPaLNJIq4UMwJxsOcYP411rVaHDNNO6NCBFQ4BLk9ST196pahdWliqNNn5jsVAMlj1wKydS8S28YeG3Zy/wDqWkC5WNiO5HpWG0t1b6jpkmol5hCzsoPB8sgKhPuc1MpWCFJvVlee6l16+SBmkt7DftQyEfKByTj19qs2VjAhjm2ZaCUEHaRzz8zevX+lTRzFrSxTbE/mSOUUfw9sEd/rVXU1u7toTDGfLd0Ru2WH8X51yTn3PQjD5DLxplm0xEZW2eYSenzE4z9KNSuEg1RlSWPY6hZnC5Eb5x+HFQXZd4riQu5KRiGN8YGc5yuPpRMfJsLaNoS8IkjeV8ht2T0x9a5XdnQlt/XmURLbz7lX5ZCQqSbuTjsF9O9ROk0cIZdrMjLuRlIBxyDRf2801/KEREJY+WqjGB7+/TmmeewW3aXzQyN5UoViAWxx+OOKyerNvQZqc0nlBS58wDfuxlRk5Ofz4NUBdXcjzTQwIsIdUXnOwgflnpVm+SZY7kqwLdTzgAD1HpUMUht5IsgKhQsfc8UlYa8iVriODTw0czFnzkngnJyTnvznim67tLyQpkzKFcso7dSfw4pLg2w02GJIykrSA7iuRnPXPpmrFyk++534e428mMjbtbrj8qdtLkvsVrXYbYtGrPMqliTjOemc9zTbdTHZ+b9qUxw7i0WeRkdT+PrWfdSSTWW9QY4YcAgH7xz/AFqss5cTNHbeUknLgHO8Z7imkS32FUvHaySSSEMw3juRx3HvTLaJLmdZFdovMTcwkOd319KkSRmmt9gZVJ5cdm69fbNQq8NvdIxYOFO0g5P1+pq79CPMrsRbxlJhnk7wf72OM/nVlkR4RmbGwAovdsDGMVQ1Bg0iPCZDnllY8AdhUtvNPJIzkhJigK7QMDB6D+dD1WpmnZ2LW9YYkd9sSv0KfMV9qozvEICiRkAEHLHJFW5mNwXklYEAg5GPnNVLlRdGNIo+QvJ6Y/z6UJhJXRAhBY4fYMEEKeoPao4Ih5aqzcsTwD1oI2skkmI4/wD0LFTxyFdj+WBtyFB7n1qm2Zqz3GGB8nEIx/n3oqHzLY8yTyh/4gDwDRVcsieePcyrWzWIxh4TkruzntTvsL7nIwPrV6GNp5vPyfLTjaTwcdqSG3QhpnJPm5JQnoBVc5qqaKVurKWaTLhSOB/QVp2tl5gadtuxiOf7vt9amWxhuLczR4HUbfU1dtbdXjQOpCn+Ad8etZzqaaGtOjrqV4omFw7BMDt70lpG73hySSSSwFa8Vl+8P2jEYHIYt1ontktoFWAKHYhmkzndz1HpWakbuDWxSjs5zdZjgLRnIJ9Md/8A69XLOBJXSKdijZyFPyk1q21thVcvhUBAPQDj1qParPBIsbNK2AvHTnkmpbu7FxVrjGt5znZgrnCMThfx/Kq8MclzZT+ai7iPkZO59TW9e208V4IpFVY2KgZPUnvUltafZwLaNGHn/KSR055OaS1VgbT1MVY4obaOC4iUzsR0B+gq9FC4s0t3JyXPmE/wj0x7V0six6f5Ud1CskpGOVyxBbjH5U/VLJ7vz42WMBCF6DjPQk05JrVmaqLYyLu20+w+yw28f20q7NI6DC47DPerP9n3Nym6BXSZudzcVZlinjsFghMcb243L8uSCGzkn0x3rQtSGd3UnaJPuuc4XHJH1pct9UxOo4rQyJ9OcXkO+VpJo8NKvfk85q7JD50LwBWC3O1F2nnknO0duOcVbfZPdXEkSM10yEq2doVQOc/hwc0t3cQxQW6IqytIrOkZzmPjAzVKOhLm3YDp9ra6fE1v+/UfeYncQBn+XNRT6kDqUTt8izRqcj5vxPekVp4bKC1h8tIpRvlMhPVTlufeq1rOJL5XFuxVpCqqOg7Af/W9Kt6PQlK6beoi6hF5ssIR1TIhXZxtUkk5z3610dxeQCZooHjlgeMYZuRgn+frXNQmE212zJ5srSPgKOCM9PX6VG17ssrlAivI0iqHx8qgU41GlqE6amza85k/tBHUOFUCOUHcQM44/E/hTTETq8ywGEw7ombf/fA4x+FULGSSGzvbt5RsiG0q6/eBOcD8/wAasJaz2cRe4QmWdYwmznJJzz+tNNvUlpJtX/rQNTuJI/Mt4kDCeIKWZSrKA3Bx3xU93qGy41WExxkOqooxuGVGO3eqWpXDQ6xDHMxby4CjAKcjIIbnv2qpqM/7uCKzzC8yIJZAMByMc0mxqN7XX9af5HR3jSx+FgbiNI5UjXdzk47j8uc1Dp10kVrgbp5AMKq5IP8AEp+vJ5qlqszSadapcyMqxld5I4xjHJ7dqq3epyzraiyCrKg3usY+VHB7+o9vetZTV3JGcabasx81zKFuLWD5pSRLjJO7eRwfTvW3ZQ2trp8UUiApsZFUn7rZI59vauT01Z31Q3TqQ92jo7L0A6gfnWg4lvLZLgM8Msu3HPPmDsfYjJJqqc+o6kOjIpb+0EttCih5bYFCinIzjj8Qao29lLq2s3E2qTvFbhWkkhjPU5wq4/Dn1rThFppGqNI0e+Z8MZDg5Y/w+xyM1Se/8/VHDxjypEMoVUzgZOAfrj8q19ra1zL2XMaMd9a29oFSFldLj5IlGFIAIwx6EjPSq8Ymh1ic38zMI/KE23J2Ac/l0BNVfMvFsGEkamLZ5ip2Useo/Dv2p7XE/wBnuY0hhuGaVMTHOeuR9R2FYuttqbKkkbK3q3mrO9rbfubRdwwOufQepp0lwl6sMqzZtd+XAGCG7/qQPwrEt7ydL+/AEURBLuhB4GMD8f8AGpIIrzMNjGg8wwh2iccZznJ9vao5x+zQQQTLdNZzDbsLOCG6Ix4/+vVdphGJdwDKJQrHdgADOMD0+nrWjbWr38ly19hVDhWIb7+0Z61kw2ImhS+dyYWLMVHG1QSAfyrGd+hqmr2ZPOsn9sLOWZ4mBcheg7gZP6VlXH2dmgMkjF5ZPMA6kqe3setXtSuI5LhEictFEqMRjAIPAAB71jTyMJRCsce/eUEsZzjBpFIkt44jNci48xldPkWNs5yOh+lV9Qjn3xxnk7AS4HXj/wDUPwonWQXcYnVI3c+XlG9OT09RxU11cxyyLBaxuQnCJjOT3GamxVxl5cqIoEdmby0+cgcbe2KpTXLXN3uMz24Ccjbj5fw9en41d1O6MWpnMSMAgDBV+76iqs0rjUMxlC7AIGwCFGc/59KcSXqiqTGtoeS7KcgBeSPT86z7m5uJbcosJVVyHycMfXOO1aSXHlTLKfLciQ7pc/fbOaz9TvmVXlEeyF2w46HA6jNVFtszmklcfY3AaKGJdxAUsuVzjOM8U28cIZJpAqqXznbgD2HvWZa6rBdTYt40BiJ5B6+1W7mZmkkRRvMgBA7Ke9W4NPUxVVSjoO+0J/ywh2syAMCerdyPUYpkNzELjcikCNSq7TyT6mqksxYQsiYI4z079PYU62djOXU7WXgBRyCfSnykc2o8XLQyMw/dy5+RcZH4+9VWnuY7WQIg2s/OTxnvTJWZk3iQBgeAc8c9ajlIji2bi3T7pyKrlsQ5O48XjuiF0JVTu4659Kma5ijVSN5LoXJHVD7VUMoVmMCAhjkdOOOfpWZNdM0qfZl5Unae9VyJmUqjRd32x5FucfSisQznJ/eOf+A0VryGPP8A1/SO3EVxGpWNY2Rj0IwKfZIyRIrqAVJDA88U+MvPFGUJjY8nacjH9DVqKJJd8YWRSvL4HPsK43Jo9pRT1QunwW9zIQsEkKgnaAaswxW8Hmo0m9WOd2c7SPalgCweTHD5krthjt69Ogq9JaxBgSceYedvXn/PWpbuXFfehQltdQs8q5CZOM4zTxHDOI28vhsKigYwO9T28ccXnKoTK8Yx1HrWyImvdMVQI3MIwWGM8kc/T1qbN3sVzW3M+K33IbdFxEV3YJyc/Q1MulyeZDMsm6D5YyQeB/8AWrYm0+IRxvMrx3B4jcgkcDoff3qxNZm509skhMZ2xcE8c/jVKD6mTqroQX9l9ssreXa6+XkM4bO5fX86tWFhFJLbsjs0VupcI3OCeoz9fWobSNoYkiumAtJB8kgOAGPY+lJbxKscgtZGUQn5mPTPbGataO5m9Vypl26t01C5Z7UkumJNmfmwPvAfSqti9u8csTktMZdpdc/Nu6Ej2/SplupCDOCZ50XaGIAxn6dRUUNyI5GkeQhJTiRZFA2sOp49aq8W9BJNKxDNcQ2OoeRGCzFSkofu3bB+gqOFjBLLHBKjh35SNiEcHnGT09MVFq9/CdV09p1eNDuRXborDoamNzLOD9li81UAD8ZUc/eA9ag0S0JJrqGeYRwGWGEQtlgBh26Dr2HQ1V1R3gvYsne0e0yFRyo7YPpVZpp7e+lxCrPGAfL3c49QDRFePGpmu4Y38wEDacEtjGD7e1K99SlCxZ1C+vL5wXgMcEGVQZA+8COT71NpfnS6NOZlZZohlGXgnIxnHrxWfeSmCBDbKZAFXLDkJg9D68+tWiPLe0mknfdPIfNkyTtwPu4Hb396E3d3CUVypLQrR3BiMVxsiWNflfdyH9z+X4VJBYj7M8IP7yRgybM+vT8ulJqogWLyUOBJJlWIOW77W+nNSwiOFlaQtHHGckKx+fI6jNJPuU9tB1xKryJG6St5y+Uyg4zjv6cYHHetS6mt5zZtLcDy4kTJjPBweNw7H2qhqlwl83lw4IWPzY1QA7ufmJ9PlFZ0ksy3JWaPEYTJK/xnPyn0zjpVczWhHJzWex1QkSTXl3QBozESsjH7ig849Scg5rK1y+DXCLdWwSaKVSFQ9h1PvxzWSlxM+rwND5rSqm5VI4Vj0XHpWteXlvdXhF0isI42CsByG9B64pSk7IlU+WV/Ib4pEF7p+6wkdbZiikk4UjOeM/rVizt4Y71fLgElo2wAsQAuBg59RnmoboSpYW7FYrm2RwzMGyMEfNgD065pJitqr7VdkZySSevHBBH161cpa3ZKjpZf1/wS0Vso9MlsbgYmdsBozwuW45qrqVwFu7KK1kTKxGNlwSC4bgn396p6aYm0oTJkXAby1UdTg9fr3pbi4ku9XQRNHK8alvOCkA57kfTtRzdB8mrfqV5preHfJdzM9wLldigfwjr1p8l7P9rvWtIkkV49iuOSVwev58+lXb6KG51K3gaE7o/ncp/EccH2qq6E6jez2riPCpjd0JzkkH8PxqblK27QrzXEqxWchWBI41VdinGSMZNGkWd1PEfNMsTvMNzMwAbBrOllnj1LzmDMZvuA5w2D0HtWhqV7Jb38KEtIhUq6oPukAdaSbbuU1ZWRPaQwreXl3HMHxMPMY53ADqCPSmNeSW97Nd20hlYOF2sp5Vj19wO1VYLyNLueMENLM37tGXoSOjeoqVrgRaRcK0kgnYlQrHJXGP0xmlKTXyEo9y9FiSK8K7jEJPNYEgjYfb61lB2tbEfZsHa0i/MSQwz0H4U4SWxV1VyI2RQzDjccccelc9YbwJYXkdBtVumQBu5NK5SiT3IuUkMMpk82RAw6fL/n9KrXTva26KyKpYqZHz94A/zNWmkWe6M1swaM5VA43EDpkmqMpjSCVpJGIfK4B447CpvqW43Vyd2iZreSR0JEuSM889D/AJ60+5nVPLeGD58hU2nBG09fxrMBEo342ltu0EZ49KddPKbhXjcptTdhTkkHjB9KV9RNK1yO5uJZ7Hy32JKxdsjqRnABqKSZmtoXgQHy1HmZOOTxUSz5uJUl2ogyWUKMk4/Sq1uyiILNKAzEFI14wTVpXRk2kPlkEKwRMgLAfMR1z64qtPH9sLpcSJ5bKX+Q8Af40l42LlUeNtkmC4B5QVVLW8TFkDGMdFAxx2zWkV1Oec+nQFWHT9ptF8pmOFz0YfWpmmljuSBhYnTbNsGdoPNMvwfLQEJkgEAcA+hzVO2hmn3lpk3DJJf6jgfrWqV9zCUuV2iTfaWRJXlGHTjnIPPf6+1VYbl4ViX7sxBKgnkZ7/lUl1DL54USecBghP757c1Dd2kS2xeQGOWMfNg9/SqVjP3vuJmUuFaJnkTALg8En0HtUF0SjwKRt3eg+6Ki86IQQ+WwJK7nG4jbntVGa5eaM73yNx4HGB6U1HUhzsi0JE8iQrjCtyT39BVZ5AmwpzJk5x1NVpZjHEsaPu+XOSOp9KfGxVYydw7/AIdzVWsQ5XHfZ0P3mcHvyKKia6UMQEQgHqRRRqI9EkjWJtyEoC2FGMbv/rVrXgdrKUwoRdBfvDhc+/qMd6Sxja41SKO7YRRxMEjZhwoPP4itkwz22oMI40uJJJSAuMxsR7VyuOzPbUulzHES2tkTtk80sD/tZ49PWtgxmAWz25DTcHdjIBP8Iz0PtVa8tjHaNthljmDf6lT9w5ANb8FvHtufM3FAqmMvlQrev4UrXBysVrO08wSu20SovELc+YQTkevvW3Hp919kLxN5MvlrtljwY9oPP4iseTTzdXCz3d2sdy7Zjb7ofA5IPqPerlrqMdm6W8rtZT7l2Mj7yeRknPHNaRir2ZnNt7Ms21+Y7kiZWkMcYbOeWb1yeKsXV29soZ4ZXt2P7tmwh59Vqtf3Vouo/Zomlkjfc21EwoB746HmquqzxJCiqpujH8hfBMTD0wTniq9RWu07FqdWeeWKS4SSIRnYW+XLEA498etVWvRcW0sVwxjVE2u7Lkux7g022RVEM1wqKOdn7wEY9MVUumkt7l7pVDxuxDI+cEEdMVm3qaRXQu22qWltZxo82+Vx5axqCuB2JJ9ewqu15MsDNMnkPjCts3sT7+3tWfdW32qaMmUwx8AyYxjjtVh5YWeeO4tym1RsKEhGIHX/APVRuFkjMku5rye3M7qiRNzwWG30Hv6Vetrl45rpIopEkK8M7FSQPb0qWOON54WhKyAAIS3G0HuB3+tSrcB7nOpOymJtoWNOQOnPr+FTa+xV+4LFFOslxdRut+i7yD82R25HT6VFcxHUkSNQJnIJ+VcHj1/Dr6VEsX+kyxiQMVzLCQRggcH8vSo9avMxxS252sgKsEOOT/Cf559KVuo7u5Oks/nrBGfO3bVYW+CWA6cHritLTY49RDPIdjbfljLYIwTyDWSZCkKjYwuUPDg/w45+hHrUthPHa+SbRwZA+HJ6AHryehpaX1BptaDI777TLBZltqwz8tySQO5PoM1vXs0cs8ybN0MUJZYxggYOCAfTv61meF545dS1Lz1XfKvG4cAf4e1TQ3MbQz/aIkSNlZd6gkKcYA+nHFO+nqS1d+hJa2a3qxyWxt49ihi+7GSRgKT+WaW6llubFCilpRgMoA5cAjP9RWZAu+wuTcqyhWTaBxt+gHT0qxOfsUshkndjG6NlOQR3+pFK6tYdncdAXNlZSOw8yLeMx8NgDkH0NRloYJdjxovzCQIcjB7r7+1PuwPt8CrDP5BJkWMYOT/9fv6VNcXEl4kYaWD7V5hlYE4xj+EfTihpMd7FCZ1tdImJMkckzEquCAAM9D/KrMMhXQglyg3qoZmict5fP8Xpx+tZupfbHfZcWx+zzONjqQcHPOR2qxqf2e2hZYFkczsEdk+VW9P/ANVLVA2mT6TDHbtKY9+GZvvNnaDzVq1lxbPNIEMTbhhcYJU+3IFZ1tdJaWs1vKgW4xkvnhwOnHcDHNOincXMqvHbROW3ggYRflG4Ee4rSMW9EZtq1xZLl7bfevdQ4c/vEydyk8fyqKPUmW7jjMARRGEGX+bcBxgGuf1x7q2J3TRLGpUpGMHcuc8j3qzrWuWdte/bIz9q82IxlcACPP8AFxWsaTaMZV0nY3ba8Bv5Q7ghSFiA52ZXnHtVVZpCpeeQAZdY3XoVB9ep/wAa5y11GGHTrqYuj3IbiPnAzxkGtrStRjtrO3gieMMw5z82wn72R0H1qJU2jSFWMtizpdyftdw86KpnfMcmOVK4xn04/Om30YtZR58r75M4XqrZPX8uoqhbzkWk8kkpkt4WIhZR1Pr/APW70XlzDc2UkrqfMXG0KcjdkcVhLU3iiXazyIiAqpXcznrgen4VBeM5fIkGGVRx/dz396pmeS5hkJcooyzHdyoHQVQW4BtgyjDbtzbjnA701HqEpGw+63wIgBD0VlOF+lQyXIltQTGViTPB6A+wqnLcxi1ENsCTI3f0x19qhu2YWe+STahA2qDksfp9aOUXP1HteTbHjdTGnQ7Rk/n6VTuLjyy8kYcoMBsnuBjJ/Go2PmLCwlbGPmDZxz0qSGKVLQSSn5h1GM9+M/55quVIy5myrNM8xR3+QOBuwOOO9Uy9xNJiCOMmXcqlgcA+o+nYVfuZY7cKvkmQkAEMuNo9agkkluxu8pdsQyu3jjPStIo55u+iZHFLuuHFyjzMi4Uqcfj/AIU5ozAiIU+VG3NxwfY/nUhdbfYSVQ8kgfwn61WcmO2gHnHIJYc5wf8AH2qlqZ2sXHkj2GByXaL5QAO3of8ACs5cGYxFhHExyABkkU+6Y/ZBIrqSSTkDkn/CoGnaF3ZowHC7c9dtNImcr7llZPIDs6sGReMHofr61QnnBRVYB3fLN/sCnmVijAqZF+84zgE/0NUnfOcARiRsHnkVSRnKWmhESvlqHByuSCByR6/hUIxhSpB3DKg849aWUqJ2ZZQy/d3EY5HaoVJmVTnavClgMZ5rRIxY4NkgheQdwb1qRyGCqv3icN/hU0IWbKLhIk/jJxzVO4YrHuA2kqMH196HqLYgN04JG08ccGipjcpnlRn60UWYc3me+w2aizgaZ0mJbEUbKAoHb5u/+FWZIRZXVlBcxNDJcHMRUbkVgedrD1otrj5VkmCfZkXeiggqCOc8/qDT76YiSJoHBsJGG+Q8oGHO4Dt6cVny2serdl4x+TeSvL5ERmBUtIdxCYzn/A9azbadoLq2S6iuLiJifmX5gSOQVPf6VNraCa2RLiCIQuof5CzjAzgg9QOc+1Z41K1gEQS4mJVVxbs2Y3PTcp+nTNLl1GnfYfFeQ6neX4uAqzKSyxOpMY9CR2Pr71EdWUzW6QWiTwK2Fi7oe49xnmq11qNnJdSS2Uw85mZTGy7TGeOR7UtzIzeQ84W2WTKjyv1Lcd6jUrR7mpJ9pi8l4Lqe3+cqxVMEfj+NMlS5Vi5SORgxIckE7uxPbmpFjeC7aaDP2Pb5jRRTbivbnPeqEmpWspu1jnvhJJIGPmqMKO4x3PvRyjUiaL7TFcPtjjldRueVE+WP3/wp099K0wKSB4kP7oEfxHtn0z2pNCEMSyQRpKJnO07n4b8PTnp2qz5DTW7EIlr5RGV2E7/93NFuw+ZPcbaW4MI+0IrM4Lrlh8vPKj1Hv600b23QShT5WfKl29FP+ecURwzyJ5ZiKyxgypcyN8qqew9ic/jTobiQW0N1dK7xh9gwv7v8fQ/zqXDsCl1IVlMaW80ETERZRnT+IehHanrfo23bscliRkY2N6euKS6fT44ne6uTGJT5aQxjv1CkVFp6wwX+94VkGz50lT5AwPAB/Wpt0ZWm5enZHv42nty6AEhkAwzew7gdqzoC1vq1wqqI3jI6pkgj68VfkubdUxK0zJyyxhQAD6bvX3HaqozBGbu2DlVPlsu7DDPr6H3o63GuxU1FpmCABWkUHkKQVyc8j6Z+tOlIaM3k0MQhfhtn3S3TJHbIqQyO8ks58zcqB0LDdu7Dn9PrUc0vk6WYroJkKPmJJI44wB1AqGrlLR3IdMKxXMwkdpB5mF7gYHHH48mr29IZLiKSQiOQK7YGCDnp6fjWTYqsXk+azpI+HZSOSPQVdbzY7lzLjYoKBN3Jzzg/Wh6FdLli1hzFczFpHEx2DJ5BHIwPrUenXwZZBt8y8YmIq4OFAGOB+FQKxEIlQEHaJBk8ZH+fwqvpV2Y55rhlMUpfd8x6E9gP69qEhM2tPvbqONWm/dmJW8tNm7J6E/571mSxqbueQgOAVLJ3BPb8e9PlDTrI0UjPPK5wqkZUDk07QrhJDcvvELxx/f28k555PfjpRFNg2o6oqX9sZbqKBpZIGkYPtVsjb75qvqRgW8SNzPLbR84JJAHIz+fP0omO+aS+dt/JREEnBB75+vNWlMf9m3YLF7xYxhsZC+ufT61aTIdnqyBrmMXVtcwef5EERRmbnO7uBUPiLWILedUhnmbe58xHACgYwce9VrW+ggt5YTbu6ojCRgRhhxjjtXL3mqWy3YtpxH5eVkIVMsBzx7fSumlC5w4iryoZrN8swMrT4mdtgTP3VHTJ7gjNY99ey3XCspxhQynBIB4z+dXxp9lqHiCO1sJnntJG3ee4I2L33fT1rQ1LTtI069utNgSWe7VQpnD/AC7ic5A9Owro2OCzlqc+l1PYMwil82F1USOOM9yBmtXSdVy7YD5d/XJA7D3rCu/JVwk0wAVuRtOMiobe7AlUIVKjjKjtSkrocXyy0PQ4r9be1dGbagfLKp9eOnrVyYsqqttlg7CRQp59Otc9oiXF7DKPKMmExuZRg1dtmeC4KRksYyQdzbcAgZIrhlDU9WnVui62yOQ7nId+ZFGMYFV3lih8uO4V92CWI7jtx/SgTR7W2BSTkDdwaxJrstdYVHd0Hykc0Rg2FSqoo1LqWRZ8RERIRgbhyPrTLmArMgE7yMrcgjAA6/5NZ63oa7ZZG+7xjIP1GatcPcDyzlmHygtnI9PrT5WiHNTLcRU5CxvGpyu3rg1DLLhcYYtIcbB3A9KonJdi/mZX7wBwc/SrEgYznyFABXC78nt+nf6U+WzE6lyvdN51xFtl2tIfmVedq9AD+VM/eRPEsT8A5wRTH3RkRSELMGyWHc44/CrMc5ZFI5bdwvqR3zVbGSd3qBTekgfMkjHIyuMY6iqssgeGWIxPlMHfjgH39zUrzuZpAHbyoxx7e1UpZ5iF2krG33sc596EglIr3E2yRBCzogPU9xT5JgvmR437RkvnoRzx61UuZDLM0YyOO/OaTdJ9mRHjkYDJ6f4fyrWxzOWtkJLMZpc7ztlA4U9PrSG4AdCIwwQ7SccA+9MEYRg5wHUYKE9M9SPWkZoju+98h/OmQCuZI3XyhtJwPrTlcI8YkwQCBgcEelRXTxKI9m4tn+Dp/wDrqlJclWJlPzg8rnkgU7XFexdlnQTTQrINo5UkfeNVmulC+W7FiU79AKpz3GSrSKcKcr75quJS8+7HyH+HPSqUSWyclCSWcZPXmiqbudx+cdaKrlfcWp9KebDM6RXczkxpsYIQoOPun3/Gq9zDNO0kcD2ojhUuFjYgMf7xrB1HVI7W2e30yWUJMA0kMvzAH2b0/lQ+qSx2sCTWh+1Qjjd8vGOM46+tc9nY9Xnjc2dOvbuO3e3ikEsTfeJwdg9SPT6UXb+Q7yXDxmYEKXiQYjz2IqGxurZk83z4oH2s0yopLqOuSD2Hp3rOga5hnkYy5SUZjaSMsJF6/e7H2qXF9R88bHQTabC1uLqGd71JeZdgVcIPU9sU64s2ubMBpHa0jAKjunvlf5muRl1JWMXnhowEIMqSc7c/cYev1rp7S3mcW9zZpDJbYGNknluwzznJ61bi76EqpEbdJZwXCi22z3TYKi4YruGOgcHB9s1Ukk1RYXG6MBl+RkfJUd198VU8T6v9nign1K1aMN8seEA46AhhlT+NcvZ6vAjK1lqk0V5zsSSLhcjp7g01T5iJVlE6zQZ5XlR5tQb90+VWUYYHpwe/St+wuLzUNXlNzqK27P8AJsTALHHG4HpXnNtqNtPNG0iOLpiA3kPnbjrx610EMWnT2Dmx1Nxe+YGKGMh857se4rRU+5mq1y7eSXX2lYbdpj5S/wDPT5JcnnA6rx2roNPkN4zvauv2OIBmAH38Dkbe/wBRWG9pJHps9sIoEkijMn7ufmZ/7yue+Oq07SxcxW0MtvJFNHszJC0u0wnHOe/PtWco23NoTbd2acxW5up/ssKm34cI+PkHpz1HpTo7uU74HjJcuN0gfleOKxnvYAxkCNul4XDZ3t3GPrTbXVmltyRCUnRyNq8nB9fWuVwOxTRt6jLIbOMysSUwPMKYHXr7e/rRJM8iXNuAhyS2Yzxu/u89apzTM2lyfbZjtJHys3ykduD6U0SPIiNH8gJwH25U/Uf1qXoaIdpF5PLbxxTyR+QisF2D5uvI+vvSaskUlnIYnc3CYbC9lxzgVQ023EN/IkshLxklTu+VgfWta7laLC7EGMEHIIweoP1oa1uiY7FGE+dYR3Lu4VzlVI+bjgAH19qnvdltYyujOHddoBP3QO+e59qpzbzCAyYt09+3Yj/PFRtJLIrRSMsrREMWJxkGi1yvJhpeoXThIvs+xPmxJnIA65+tNuv3sL2yq0kgJaWUn7g6g8d/WqtheeTIYpJMKHZVJHTI4qwlx9nsZFaFGR3wV7tj+LP9Kpx1M1L3dxAfstnODI8bCMhQowxzyD7VYju447RFBkBlCgkn5emD+uaxwyywXmwsrl8M+cgL2z+FV9Tu5Psf2RZd0YQFWPH4fpT5SHUS1N8eQfD11A0/+kWz/LuH3gTxj6etY9vdXUFpf3sUfmWkjBJAT07BqpSz3M1jG1lDI2xMNJCPmzg/Kfw9K583Nw9thLhYlcEsu7hj6H/Ct4U9zkq17Wsav2y3i3PKkquAVC78Zz/F+fasnW7e1iv4riHU49ReZNzPErKVPcMD1NQwWk9zFG8dxFK8uQI1mAdAD0IPFWYNMaCR5LxU8iFtzbHyQM+1dKjynA5Oeg26uZ9J0iC5tWHmXJYMg4IHYe1VvDM7av4jhm1J5BbIRJJ5f3sD+EfyqtqV/e314HRWnWTLbI4+Qegx9OK3vD1pdeH57WfWLdFjEXnMr8Pk5IBHX0prTUL3dih4tFvNe3s0OIRI5faByF9DXN6dMIjujG49APWrGvXIuHIBZppSXbbwMk8jFOsYo44FkQ4kjOcHofYf40rWQXvK50tlqElo1uJLl0QfM2MEpntVmPUbi61GSSBGPmARs2M9OfzwK52KXfMvnq4hLAuz8ACrx1/ybP7NZ/ZUggZmD7QJJM9iRyah076lqu1szTuryN74mViig4YjjIx2FRjUo4ZnFq3zknZJ0xkVzdzctdTu7sC5GQCcE+wzVjTHSZ3YqNqgEZPQ1Ps0kV7ZyZp2UbrC7MQJCxUHHXP9fateFPJELMGEykDB6YPTFRRSIksUIbLEGQsRwpIp0jiSQs7sQpGHI7/57VjK7Z1QiktBfLO2d4mj/dncd/O6o47ljbA5UNGM5PcHqaCzKqOgyzHDD1+v4VWV2iuGAjIQfN83ODiklcG7Ez+Q0hkOWLL074HSnSvlEKqVXaANw5PqR71VmkCzfJHhQoCknn3/AApszuYg7NlYgFHPY9qrl2JcrbAzb28xJPlbJA68dvx/lVOSaT7IsY4ctyW9/Q0rufIZY24HIAqsb0lFjcBgOcY6c85NVYxchCrLII15Yk8g/ePr7VJJm3BfzRkdB7981nvOTMHhycDOPSqod2myzjLEYJ5FXYyvYuz3LNFsUqSDk57eoHrUKTFBmf7p5A9qpljI4dTnYSdw71XaWUsAFJY5z7CmokNli4vGKkjawLZC471T8wSBjK6nPJGOc+1QvKyKdyEjPfn8DSnGTkAfxDFaJWJuMk8xUIcDJ5I68VMHCFMHkL6dBVaaVQCFJdiQdx/lUTSsw5NVa5HNZlv7RD3zmiqOT60U+RC9oz2W9eCRtqo0O4fPvOMN3IxUl1fMojgnuv8AVr+7kCDt64rFkdZxMJUZZieo/h9MD+lQTo0aGFJTMijcG5+b6jqK50jvc7bGxeMJI5mjL3IVN0vlkBl/xHtV3SfEU6tFO90j28LhmidQFYAYHHTNciZVmkCrcvDM7fMJVwoXHqOTzUD/ALiVEPkqWO0ysSF5/wA9atRtoZOprc7DxC0c076lq1pcFJSGV7UgBd3Kgnpn2qppsV7qcCxwSLPvJCxOfLdT7E8VzbXd9AJI4r5ZIs+Yy5yjH6dKYmtvIiRy2/8ApEZysgJDAdhkdRVqKRDm2zqZDqU9tJFqEMUdtb4jIYZ2nOOQO/Nc9rFullK5gl8+dR87ldqkdtv0rKmv7zZFHMzQyKxYTZPP1qG1nuXdoxcDbJwdx4IzzVWJbvuC3DM5ZHKMOQUPQ+v1rd0vxFcWd40sMwS7ZdjtJyJFx396yhLBF51uIVKgEiYjBLVl3ikEiMqQT1JoTD0O7/tWa+gWM3IGwBsEDuTnmpRraxASrI0dynQ5+8PQ15zHdSWrgoSGHQjvWja6wZI2VyvnArtbywwOKTgNVGj0XTtZRp2k8tRhzJuI7n2/wrWtpWa8u7l4UHmwb06EMc8ng8GvKodTvLidFkdDjgKnBAFdbp88saLv3iQBXG49R1zWM6aWx00azbszrJZHuESHAUMo+8SSpqe1eS28t5TuRGHCcMe3SqbXcQ04FJlaT75Cjndjv6fhSLL5tokiloyyYOeQW9q5nE9FS1Jbza9w8kM+/OQRjGP/AK9TxX9uLG2iXBB6seeQen4msj7YkUBWQbHDD5vUf1qhJfPZ3R8jLxFtwJHQ4xmhU76Euso6nS3d5mKZJIisRHA6DI6E/jTLC4We2luJZXkf7pwR0FZjXLiBm+dll5Zm5x6VDbeULdUTAKZAKHgg0uTQFVuyVJCsFzIqgoW3DPQE+lXbvZmOKOM8gO7KflOR6dqz5n8hUiZkaMjAYnH4+9KJGLhB8xmwOTjge9Nx6gp2Vitdylby3iQ7UlO+ZOm7AODWbfXIJQKrAsDzuGAe3HfIrSvy5ulljVSyqQ5PYehrNu4ftn+kLbxwkkkCI/KPb/61bwinqcNaTTaRmNrD27yBJJIgeCwOCOOwrImvPO2qgTa3XnBJ/pT55EnBMuc5wMtgmsO4kCT7Y0Kgn8a6FFHJKTe5sC4Rl8uXH1Xpmuj8OyJ/Z+oSiRVaFEYRyDKyrnla5C2O9FBZSgJBGegqwsE5LI0wjjYYDcnjPGaYk7Hbt4hj0ZhPpsC2lzNGTvUglBnoK5DUtUudQumlaXzTyxeQ8tzn5qzbmCRgN0jE8Bj2qaKGKxVknL+Y3fHGKYSd9B8scSj7RcM75b5VRcEmp0FxaReWYIikhG1WO5g30qCB0S6Ro5VnC8btpO36euK6LQLDY91qLCea3h4il6ZfPQ++KTaQRVzAaPUJDI8rSmML8wAOAPemC2V4wAikLzu+tbdz4oRFltVXFoWLPGT87E9QarGGeytIpbq0dILkFoWdcbwD2qbvqUuXoc5qsLWd8yNMJXAHzg5AyO30rV0OScgmMDEZ3FjzVDUsnUlQENsAHycj6VqaOPKdNsmwYO7I4qpbEx3OpRG2l1YszIW3e3rSC4KqWeRnKYYA9BkdaoESEFfNBi4BxzgDtTbh8sBGCpcAexHauXl1OznsjZlvXn/fEdRt3AAAj6VHJOGzv27z8/TjFZjzxQoFDlxwCCcBfpURuQ3TlA+cnjd6ClyDdW5LOVNzI4k/dqM+2cfyqCa8V4FRELsvc8AnvULyNJ5o2jB+bAPaqjTFjiNmHvjBWrSMXLUkubxm+VUCZwu5fQVVlm3E7zhe5XnJ7ZolKcqW2+pznNVJpDIoVtiIOmO//wBerSM22ObbGg2uSW5K56moLicsE3Mdi8ADrVWWfr8xyMYAquZSVAHXOelWombmjQ85DHkfMc8E1Wa4LzZDlSM5Palg069uoy8UDuoPOK27fwq7vExdijDJGMEEdatQuQ6lzmncsSTnmml2J6npiu31Dwy7acyWsCl1bKOOre1cU0TpI0bqVdTgqeoqnFx3IvcfaW7XMuxSAcVattPc3DRyr8ynGKk08GOVZEGCvOO5ro763DLHfRggMAGNc86jTsdFOmmr9ioNEhwM8H6UVOLogcv+lFc/NLudVodjUguVbcXkdgeCAc//AKqr/a4UeRZS8uAVEinDL6fWspLkwQuuMgn8aqrdyENtUbTnIz0roUDJzvZG3fXkkgUKsPluoG9VwVx0z/WuX1Oe8XalzuMZJKFu4781M1yySDEh9COoNVNTupbiTExb5OAOwFapWMZsjhuJI2K7mRG4OPSuj0iNra0k1C43NgFY2XsfWuUIKqpJB3e9bejXMU2ywkaRIpCejDBJ+vT607XM4s0PmvtFS4eVpLsPyo5yDxWbM+AA0f7zp7/lVjTIPsOuSQvvkWNsK0TcH0571P4rMH9rPMJSfMQN8uDig0TM61S4ldvLRpI1BOegFWtNsG1C8jiLbYc/NIMYUe/pVVL142it4iqA/KxLcc96uarcpHcmPTYdtmQo65JIHJzTQrli90iJVY295A4yV8tm+biucmjWGfBYkAZJU81qwLZNO089zHbjvFGCeg7H3qvfS200w8uclBwqeX2osJtMS1nRnZ23HauN3ALex/xrptKuyBHvMTR91PJB7c1yAR4t5jOVA5JPAzW5YuHWMCMiVRy4qZLQqLaOrjvpgwjbAjB3IVXgj0NaIuzJYxwSKY5AT+8HYelYNpdt5IgjVWDDkdCKka7kiQwjDIByT95R6A+lYOGp1RqWRsMQbLySfMUMCxYfN9aJwDBtmw3UqTwQDWdFdnADEqEAIc8Z9qR9Q34Rm2gduefp/hUqBTqq2ps6bcGO3hXBkiQ8fNgH6Cq99P8AZS81oFVHA+Vj/KqUcwaE5BAABUg44qN7yOSIrOoDAjO7p+FPkuw9rpY05rizawAld0kGCQy5ArOa6FyYY0OCHyCp5XFRNIUJU4ZHYldvOOKrQTR27SOQGHXCjBFHJ2E6l9Ga0UvnyvCVLAoQc8c1VumbyjGZPKLD7qn7zdKZbzkusscKhZByN3Jx3pl5dqwGUDEfeBH3fxqkrESkmtTI1XTo1CS4LFeGVvX14qhFGgYLPGNxOcsM4roYpo5VUOrMsbHOBzn/AApfKgkmhYw/dHLdR+Nac1jLlTKSwxfaQ0sZjUJtAjUc/h60jeU5LSYEp+6MECrty9tIzICQSMkepqhcSApuXMe0dfWhO+5LVipcMsFud0YYhvlA559TWPfzGWVTKpLZycGrt5fLJIEUhmyB065rPuLdsPKFJA44561a0JbJo5gCrQx7Bj7qevrXT6D4oWK3ntpUUtIBGkjjKoc8kj6d64uXzoX+ZWjIAFMlm3qoAwR1PrTsLmsb+o2trbXEwE6TyPJnfs4A9c9qg17W3vIYYY3kMMedm5skf4ViebJt2hjtznFJsIGSOOlFiebsWbKOSQ7h9xODzz+FdVbsFtTvUEqMANXM2kRCoQSCx/AVtebhhgnYRznmolqaQ0L0MygudygHt0yKUzFm+QlQ3B+mP0qhE0Kt15zkZ70jXQQMzFQxBAHtWfKacxNNI2dmAI3xzjOKa8rNjZ82CDleKgS5/dFNxGeuKhluUjZSSSSee1NRE33LAnZS4Kl2HqearPL85LkdOc9KgN00jYt1ZmOOAMmrNlot/qcqHynihbI8xhxVqm2RKaRRu7ny2ITGCfTqKSKG6vo2EEJ2rlsnjPsK67S/BaiZDeOHHI2ngCuns9Ht4YmQQcKMfMOhzXVTwkpdDGVW7POdN8MXV1IBL8g27yD/ACrsNE8LW1tMkrQC4CLl4mbBP0NdRFZkgKgGcgc9TV2OKNnYXDEMF2pIvBGPX/GuyGCS3MXU7HM2OnFYHfywiZH3TyK1JLOZZfLZACqgkeuavQxRrKgL5Rlyy/4e9RwozzAPKVHRXbkcdB/9at40Ix0E5EUVmGjiCsyLnnPRTXBeONGEFybmNRktlmA6+9eh3jzNICQm1Rgqh4b396oa3FHfaasSY7kK/UH0JrPE0lOGm6HFnldkA6BgOvTvXTaIFmSSyuB8jj5frWQ8Jtr1opE8sjqvTB9q07cMrJIhG5OQa+erRvod9KdrMik0fUEdkVAVUkA46iiupTVrYopaVAxHI44NFc/tanY6+Sl/MeZvcyjBQ8dDx1qGRwgIGFz83I70/wCz/MFU4x3zT2s23KpYFx+VenY4OYrSyb1BYIAD/CO9JIHeOWSMALn5gBwK1LbSppG8wmE4IwDn/CrI8PzMHTzYwOXOCef0quUhyWxy5H8qPSu4t/BnmKGMyYIBxz3qzceBhBb+b56OcldpBxVezla5F0cUl1cIkcYZo1OME0zZJI5G0uezdjivQn8DOVjdrtMBcnC/yq23geOO1jV7ssB8wG3161aoTetg513PMRbl3C4Oc8gdRVuK1eOUvbTBHQgruI5Nept8PbGGGCVZ3Z5QMhhwM5/wq0vw+sVL7JW+T+FhkH8av6pU7C9pE8r+zz+VDJcJEgjBKkIDu55JpLSza4ZpM4KksVQAGvWV8DaY82xJJhtXeSe4+lLJ4FsY7eKaGR1RiQM9eDVfU6vYFWieYQRQQrIu0Sbhg7xjHqPqKdAXTAThB09fevU7rwFZ/Y47hSNjE5DEkgjqRUEfhKwEYO3CldwH+JqfqNQpV4nn6z4VvJO08ZZhz+dJJMWYRs4JPbNehy+DbaS0iuAQEIHy88g+tJaeELIiQskchBwS49ehHvTWAqNj9ujz8XbSq0fPyjG7piobmaZsI5JXG4Ec57V6xB4O02NpmaBCY1/Mmk/4RmwVXV0yUUkY9c/yp/UJrqhe3ueTNctE/wC7UHAAzng1Ot2zfLLySOPavTx4Wsl83MUYMfBwO/tUM3ha0Zs+XFwwXp3x/Kh4CYe3R5uJmNxHgqY93C9cfWnSyhlHAMmDnBr0OTwpYGGRDEm7eNrDgiqkvhK12I6n75OM9RzUPBVEP2yONtJC0C/Psz1AFIxZLnbGDtIzk+tdPP4QUPm3umRcfMCM9T2rOn8NTRlQtyrKx7jpg4rF4ea6Fe2RQgc+YUjIcn5srxhvrSxb4ZzJJlgxzlO1XH0We1EhWSPCybGHPJxnPSqEUhhk8oqpUn0z2rJwcdy1NMamyQF2Xc6kj3/CoCiiNmBG4/dHfrTZzsfMfyunX0PvUiSeYoKKFLDBzzU2sFylNp6Om5gxYnqRnNV2gxEWjToSCoODWkspjjYIT2zn1qGFso7MoOc89xzT1C5nmMbCXt2LqODnJJrPktzI+6RSuegx1roQqg7ueOg9qZjzNo/izx/hVIT7HOpbEM3VSv606O2JYgglu1bzWTuMJ5aqTjFXY9BmeeAecgEhxnFNJvYm6Rz6RGFcNz6e1OMx+ZWxyfzrt7LwbHcTbJZyGc4G08e2a19I8AWruzs4byiVOTnJFbRw05dBOqjy8NPIBGkbNhgRtWpzomqTMR9mcHPI6GvV7LQrKI7in8WTjjOK17WxBlZgQ2AZDnrgV0wwDfxOxnKs+h5HaeFtTndElYIg6tjp9a6Kx+HwSbyr075R0Yn5ceteg2iQy3KxyR4R/lbb2z6U+ezY3c9rFIT5WQrv1wOf5V0RwVOO+pk6smcpZeHbG2Q4VSUbY4H8Q9cVqwWlvGjm1A8r7oDDpn1q48PnujoqK4UKc/xe5qxBaifb5Z8tJWAZeo9Aa6YUow2RLb3KixRK4gMWUBX51OeankVCUDKFJbcSOhA6VJJClteeTlnVNxJPU44pk4a2fDYbdGSea1RHqNLQG3QzR7WUkkp6VFLaPHEkrKrQNwrL6nsatSMkZx5KMqx7Hyec9yvpTb22SKfbE8nkSAMqsemKm+uhSZnyRCOZfOdUdXC7WHIpsvlyEgnoDxj3q1s3rOJsSHaGBbrntTorZZtOmkjO2X5WJPQg9v8A69S3bVjTM2VQsixklcAYb+6e1Jtj3K7qsh25OwdD9KnlmKlAyI3zAk45POBStGYjNgLg5BxUvVjRyHjrR0e1jv7RVZd3zYPKn/CsXSbgT246ZHDD3r0O8gjngaIA4ZmJz6gV5pLGdO1KQA5DkZxXjY2jyy0N6U2tzUMSZPT/AL5oqdfujKqTiivN5TsP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions in a patient with AIDS-related Kaposi's sarcoma who presented with simultaneous cutaneous and gastrointestinal disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from van den Brink, MR, Dezube, BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesion in a patient with AIDS-related Kaposi's sarcoma with a yellow perilesional halo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AIDS-related Kaposi's sarcoma appearing as plaque-like lesions with breakdown of overlying skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8441=[""].join("\n");
var outline_f8_15_8441=null;
var title_f8_15_8442="Sexual activity in patients with heart disease";
var content_f8_15_8442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sexual activity in patients with heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8442/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Stephen E Kimmel, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/15/8442/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/15/8442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity is an important component of quality of life and thus is of great concern for both patients with heart disease and their physicians. Cardiac patients are often fearful of triggering myocardial infarction (MI) during intercourse and may therefore have sex less frequently. Another component of this problem is that patients seeking medical attention for sexual dysfunction often have concomitant cardiovascular disease.",
"   </p>",
"   <p>",
"    Several aspects of the sex-MI relationship will be discussed here, including the cardiovascular effects of sexual activity, the association between sex and MI, modulating factors that may decrease the risk of MI following sexual activity, and the treatment options for cardiac patients with sexual dysfunction. The risk in patients with other cardiovascular diseases will also be mentioned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR EFFECTS OF SEXUAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity, including arousal, erection, ejaculation, orgasm, refractory period, and resolution, is in part dependent upon changes in the autonomic nervous system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual arousal and penile erection in men results from stimulation of parasympathetic nerves in the penis, reduced activity of sympathetic pathways, and the release of nitric oxide from the endothelium [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/1\">",
"       1",
"      </a>",
"      ]. The importance of nitric oxide constitutes the rationale for the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      in men with sexual dysfunction. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Sildenafil'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link&amp;anchor=H2095400#H2095400\">",
"       \"Overview of male sexual dysfunction\", section on 'Role of blood flow and nitric oxide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early sexual arousal in women appears to result from sympathetic nervous system activation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"       \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main outflow to the cardiovascular system during sexual intercourse is sympathetic and is mediated by outputs from the brain carried by efferent pathways originating from the thoracic spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hemodynamic stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies, performed during sexual activity in volunteers who were monitored in the laboratory, found the following changes during orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peak heart rates were 140 to 180 beats per minute",
"     </li>",
"     <li>",
"      The mean increase in blood pressure was",
"      <span class=\"nowrap\">",
"       80/50",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Respiratory rates and tidal volumes increased significantly, approaching values seen with moderately severe physical exertion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This perception of a high cardiac workload and risk associated with sexual intercourse was reinforced by the observations that patients with stable angina often noted chest discomfort during or immediately after intercourse.",
"   </p>",
"   <p>",
"    However, the results were different in studies performed in \"real-life\" settings, in which married couples were monitored during sexual intercourse in their own bedrooms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The mean heart rate at the time of orgasm was 117 beats per minute, which was lower than the heart rate during normal daily activities (mean 120 beats per minute). Although the blood pressure was not measured in these studies, the mean estimated blood pressure was",
"    <span class=\"nowrap\">",
"     162/89",
"    </span>",
"    mmHg. This value was based upon the blood pressure achieved during exercise to a heart rate similar to that during orgasm. Although such a calculation might underestimate the peak blood pressure at the time of orgasm, because it does not account for the sympathetic response to arousal and intercourse, similar values were noted in another study in which the blood pressure was measured [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard clinical measure of exertion is the MET (metabolic equivalent of oxygen consumption); 1 MET is defined as 3.5 mL O2",
"    <span class=\"nowrap\">",
"     uptake/kg",
"    </span>",
"    per min, which is the resting oxygen uptake in a sitting position. Sexual activity is often equated with 2 to 3 METS during the preorgasmic phase and 3 to 4 METS during orgasm; this is equivalent to walking at two to four miles per hour on a level surface [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/7\">",
"     7",
"    </a>",
"    ]. Exercise testing is often used to assess both exercise tolerance and tolerance for sex [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical implication of these observations is that sexual intercourse is associated with a modest increase in myocardial oxygen demand that lasts only a brief time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/9\">",
"     9",
"    </a>",
"    ]. This has been confirmed in a number of studies that found that sexual activity contributes to only a small percent of infarctions (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk of MI after sex'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Other reports have evaluated the effect of exercise training and sexual position on the cardiovascular response to sexual activity. Exercise training attenuates the heart rate response [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/10\">",
"     10",
"    </a>",
"    ] and reduces the small risk of MI following sex (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Regular exercise'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one report, 16 patients with MI underwent a 16 week exercise training program [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/10\">",
"     10",
"    </a>",
"    ]. The mean peak heart rate during orgasm was significantly lower after exercise training (120 versus 127 beats per minute prior to training) and maximal oxygen consumption increased by 11.5 percent. There was no change in heart rate or oxygen consumption in six control patients.",
"   </p>",
"   <p>",
"    It has been assumed that the man would perform less physical work during sexual intercourse if he were supine. However, this does not appear to be important. In one study of eight normal men who were monitored during sexual intercourse with their wives in their bedrooms, there was no difference in heart rate (114 versus 117 beats per minute) or blood pressure",
"    <span class=\"nowrap\">",
"     (163/81",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     161/77",
"    </span>",
"    mmHg) between man on top or man on bottom [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/6\">",
"     6",
"    </a>",
"    ]. A second study found a slightly lower minute oxygen consumption for men in the supine position, but this lasted for only a brief period during orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Response in stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;During sexual intercourse, the increase in heart rate and blood pressure is the same as any form of exercise. Thus, patients with angina may become symptomatic during intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. In one series of 35 such patients who were monitored during intercourse in their homes, 65 percent complained of angina on at least some occasions and had to stop activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate medical therapy, usually beta blockers and, in some cases, prophylactic sublingual nitrates, can prevent angina in these patients and permit a normal sex life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with chronic coronary disease who undergo revascularization with a percutaneous coronary intervention or bypass surgery and who are asymptomatic do not have an increased risk of symptoms during sexual intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK OF MI AFTER SEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to determine the relative risk of MI following sex, a case-crossover design has been used. With this method, each patient serves as his or her own control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/14\">",
"     14",
"    </a>",
"    ]. As a result, the effect of confounding chronic risk factors is virtually eliminated, which is important because people who are sexually active may be different from those who are not sexually active in ways that would be difficult to account for if different individuals were selected for the control group.",
"   </p>",
"   <p>",
"    The case-crossover design was used in the Determinants of Myocardial Infarction Onset Study of 1774 patients who were interviewed with one week of an acute MI; 858 patients were sexually active [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relative risk of MI within two hours after sexual activity was 2.5; there was no increased risk of MI beyond this time period. The risk was reduced in patients who underwent regular exercise.",
"     </li>",
"     <li>",
"      The relative risk of MI after sexual activity was similar in patients with a history of prior angina or MI or no prior cardiac disease.",
"     </li>",
"     <li>",
"      Only 9 percent of patients had sex in the 24 hours before MI and only 3 percent in the important two hour time period. As a result, the absolute increase in risk was small, as sexual activity appeared to contribute to the onset of MI in only 0.9 percent of patients. Many other triggers of an MI, such as psychologic stress, anger, or physical activity may cause a greater increase in absolute risk because they occur more frequently [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results were similar in a second case-crossover study of 699 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/12\">",
"     12",
"    </a>",
"    ]. Only 1.3 percent had sexual intercourse within two hours of an MI; the estimated relative risk of an MI in the hour after sexual intercourse was 2.1 overall and 4.4 in those with a sedentary lifestyle.",
"   </p>",
"   <p>",
"    Although sexual activity can trigger an MI, what is important to the individual is the absolute increase in risk (ie, the risk from sex minus the risk at all other times, referred to as the \"attributable risk\"). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link\">",
"     \"Glossary of common biostatistical and epidemiological terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since sexual activity is a transient trigger that increases risk for only a two hour period, the absolute increase in risk is very small. Based upon the result from the Determinants of Myocardial Infarction Onset Study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11\">",
"     11",
"    </a>",
"    ], a 50 year-old man free of cardiac disease with an annual baseline risk of MI of 1 percent would increase his annual risk of MI to only 1.01 percent from weekly sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/15\">",
"     15",
"    </a>",
"    ]. Even a person with a high annual risk for an MI of 10 percent would increase the annual risk to only 10.1 percent from weekly sexual activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Modulation of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two factors appear to modulate the risk of MI after intercourse: exercise and medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Regular exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both of the case-crossover studies described above, the risk of MI following sexual activity was reduced in patients who exercised regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In an analysis from the Determinants of Myocardial Infarction Onset Study, regular physical exercise at levels of &ge;6 METs modified the association between sex and MI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/14\">",
"     14",
"    </a>",
"    ]. The more regularly a person exercised, the lower their relative risk of MI from sexual activity.",
"   </p>",
"   <p>",
"    These findings are consistent with observations that regular exercise reduces the risk of triggering MI and sudden death from heavy physical exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] and that exercise training increases the aerobic capacity and decreases the peak heart rate in post-MI subjects engaging in sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/10\">",
"     10",
"    </a>",
"    ]. In another analysis from the Determinants of Myocardial Infarction Onset Study, 4.4 percent of patients with an acute MI reported heavy physical exertion within one hour of the MI, with symptoms usually beginning during exertion (relative risk 5.9 compared with less strenuous or no physical exercise) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/16\">",
"     16",
"    </a>",
"    ]. Importantly, the relative risk was inversely related to the degree of regular exercise before the MI, ranging from 2.4 to 107 in patients who usually exercised five or more times per week or less than once per week, respectively. Thus, people who have been physically and sexually inactive may require more careful medical advice and monitoring prior to resuming sexual activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other potential modifiers of risk may be hypothesized from studies of patients with an MI and the proposed pathophysiology of triggering factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The increased relative risk of MI from sexual activity makes it similar to other triggers of MI. Among the proposed triggers are enhanced hemodynamic stress, resulting from an increase in heart rate, blood pressure, and myocardial oxygen demand, as well as increased platelet aggregability and coagulation in combination with a coronary artery plaque that is vulnerable to rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, medications that reduce heart rate or blood pressure or inhibit platelet aggregation may reduce the risk of triggers of MI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers reduce myocardial oxygen demand and can minimize or eliminate angina during sexual intercourse. The Determinants of Myocardial Infarction Onset Study found that beta blockers reduced the risk of MI following anger [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/20\">",
"       20",
"      </a>",
"      ] but not sexual intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      lowers the risk of MI following episodes of anger [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/20\">",
"       20",
"      </a>",
"      ] and the morning waking hours [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/21\">",
"       21",
"      </a>",
"      ], both of which are known triggers of MI. In the Determinants of Myocardial Infarction Onset Study, aspirin therapy was associated with a nonsignificant reduction in the relative risk of MI following sexual activity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISK OF SEXUAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of an MI or other cardiac event (angina, arrhythmias, exacerbation of heart failure) associated with sexual activity is low, there may be an increased risk in patients with a high risk cardiovascular profile or those with established disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk assignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of sexual function should be performed routinely in the initial evaluation of all patients with cardiovascular disease. Further clinical evaluation is based upon estimated risk, which must be individualized to any particular patient.",
"   </p>",
"   <p>",
"    In 2005, the Second Princeton Consensus Panel on sexual activity and cardiac risk published recommendations for the initiation or resumption of sexual activity and for the management of sexual dysfunction in patients with cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22\">",
"     22",
"    </a>",
"    ]. The recommended therapeutic approach, which is described below, was related to estimated risk (",
"    <a class=\"graphic graphic_table graphicRef71511 \" href=\"UTD.htm?43/3/44092\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large majority of patients are at low risk. This includes patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No symptoms and less than three cardiovascular risk factors (excluding gender)",
"     </li>",
"     <li>",
"      Controlled hypertension",
"     </li>",
"     <li>",
"      Mild, stable angina, although the antianginal regimen may need to be altered (ie, no nitrates) in patients who are treated with a phosphodiesterase-5 inhibitor for erectile dysfunction (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Adverse interaction with nitrates'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Successful coronary revascularization",
"     </li>",
"     <li>",
"      An MI more than six to eight weeks previously in patients who are asymptomatic and do not have exercise-induced ischemia or have undergone coronary revascularization; it is probably safe to resume sexual activity three to four weeks after the MI in patients who have undergone successful revascularization and in patients without exercise-induced ischemia",
"     </li>",
"     <li>",
"      Mild valvular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients at low risk can be safely encouraged to initiate or resume sexual activity and can be treated for sexual dysfunction.",
"   </p>",
"   <p>",
"    There are limited data on patients with pericarditis, mitral valve prolapse, or atrial fibrillation with a controlled ventricular response. These patients are not at high risk and should be managed on an individualized basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intermediate or indeterminate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermediate risk includes patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No symptoms and three or more cardiovascular risk factors (excluding gender); a sedentary lifestyle is considered a risk factor",
"     </li>",
"     <li>",
"      Moderate, stable angina",
"     </li>",
"     <li>",
"      A recent MI (more than two weeks but less than six weeks); as noted above, in patients who have not undergone revascularization, the risk can be assessed with stress testing, which is often performed during this period",
"     </li>",
"     <li>",
"      Asymptomatic left ventricular dysfunction with left ventricular ejection fraction &lt;40 percent or New York Heart Association class II heart failure (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Noncardiac manifestations of atherosclerotic disease, such as peripheral vascular disease or prior stroke or transient ischemic attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients at intermediate or indeterminate risk should receive further evaluation, such as stress testing, particularly in patients with a sedentary lifestyle, which may permit restratification into the low risk or high risk category. Consultation with a cardiologist may be useful in some cases for assessing risk and management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     High risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;High risk includes patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unstable or refractory angina",
"     </li>",
"     <li>",
"      Uncontrolled hypertension",
"     </li>",
"     <li>",
"      New York Heart Association class III or IV heart failure (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An MI within the past two weeks",
"     </li>",
"     <li>",
"      High-risk arrhythmias",
"     </li>",
"     <li>",
"      Obstructive hypertrophic cardiomyopathy",
"     </li>",
"     <li>",
"      Moderate-to-severe valvular disease, particularly aortic stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients at high risk should be stabilized by appropriate therapy and further risk stratified before resuming sexual activity.",
"   </p>",
"   <p>",
"    As described below, treatment with a phosphodiesterase-5 (PDE-5) inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients taking a nitrate. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Adverse interaction with nitrates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SEXUAL DYSFUNCTION POST-MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual dysfunction is common in patients with cardiovascular disease because of concern about risk; side effects of medications (diuretics, beta blockers, lipid-lowering drugs); the coexistence of shared risk factors, such as lipid abnormalities, diabetes, smoking, and hypertension; and the presence of psychologic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/23-30\">",
"     23-30",
"    </a>",
"    ]. Sexual dysfunction after an MI (most often erectile dysfunction in men) is estimated to occur in one-half to three-quarters of patients; although less common, sexual dysfunction is also seen after bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Both men and women have less sexual activity and less satisfaction with sexual activity after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=see_link\">",
"     \"Erectile dysfunction in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac patients may have psychologic causes for sexual dysfunction, which are often due to perceptions of their illness and should be ascertained in the history [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/33\">",
"     33",
"    </a>",
"    ]. Worries about triggering an MI or sudden death and depression and anxiety about a newly diagnosed illness, especially the occurrence of an MI, can all contribute to sexual dysfunction in patients with heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/28,29,34-36\">",
"     28,29,34-36",
"    </a>",
"    ]. In a report of 130 women with an MI, for example, 71 percent noted a decrease in or no sexual activity, often due to fear on the part of the patient or spouse [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, many physicians do not discuss this issue of sexual intercourse with post-MI patients or their spouses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. For these patients, attendance at cardiac rehabilitation, treatment of any psychiatric condition, and reassurance of the low attributable risk of MI may improve sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/28,38\">",
"     28,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link&amp;anchor=H16#H16\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\", section on 'Depression and psychosocial stress post MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since sexual activity is often equated with physical activity, exercise testing is often used to measure exercise tolerance and tolerance for sex [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT OF SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual function is an important component of quality of life and subjective well-being. The prevalence of sexual dysfunction, especially erectile dysfunction in men, is higher in those with cardiovascular disease than in the general population. General issues about the evaluation and management of sexual dysfunction in men and women are discussed more fully elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of sexual dysfunction in patients with cardiovascular disease is based in part upon the estimated risk as described above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk of sexual activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations from the Second Princeton Consensus Panel are primarily based upon patients with known coronary heart disease (angina, MI, post bypass surgery) but must be individualized to any particular patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22\">",
"     22",
"    </a>",
"    ]. Perhaps the greatest cardiovascular risk is the enabling of moderate exercise (via sexual activity) in previously inactive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk &mdash; Such patients can be safely encouraged to initiate or resume sexual activity or to receive treatment for sexual dysfunction.",
"     </li>",
"     <li>",
"      Intermediate risk &mdash; Such patients should receive further evaluation in order for restratification into a low risk or high risk category. This is often achieved by stress testing, particularly in patients with a sedentary lifestyle. Consultation with a cardiologist may be useful in some cases for assessing risk and management.",
"     </li>",
"     <li>",
"      High risk &mdash; Such patients should be stabilized by appropriate therapy and further risk stratified before resuming sexual activity or being treated for sexual dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important component of the treatment of sexual dysfunction in all patients is correction of reversible causes. In patients with heart disease, this includes reassurance in patients in whom sexual activity is considered to be safe (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk of sexual activity'",
"    </a>",
"    above) and drug-induced side effects.",
"   </p>",
"   <p>",
"    Among the cardiovascular drugs that may be implicated are thiazide diuretics, beta blockers, and lipid-lowering drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Consideration should be given to the time sequence of initial symptoms and changes in a patient's medications, and, when possible, alternative prescriptions should be pursued.",
"   </p>",
"   <p>",
"    Another important issue is that phosphodiesterase-5 (PDE-5) inhibitors should",
"    <strong>",
"     not be used",
"    </strong>",
"    with nitrates in any form [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43\">",
"     22,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Adverse interaction with nitrates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PDE-5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphodiesterase-5 (PDE-5) inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    are widely used in the treatment of erectile dysfunction in men and can have important effects in patients with heart disease. Most of the published data is related to the use of sildenafil. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Vardenafil and tadalafil'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Sildenafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    can improve erectile function in patients with stable ischemic heart disease. This was illustrated in a report of 357 men with stable chronic coronary heart disease in whom sildenafil improved erection in 70 percent compared to 20 percent with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/44\">",
"     44",
"    </a>",
"    ]. Sildenafil is also effective in men with hypertension, diabetes, and nonvascular organic or psychogenic causes for erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of male sexual dysfunction\", section on 'Sildenafil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    has two important cardiovascular actions in patients with heart disease: it can lower the blood pressure and it can interact with nitrates&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/39,43,45\">",
"     39,43,45",
"    </a>",
"    ]. Sildenafil is a vasodilator that reduces systemic vascular resistance. It lowers the systolic pressure by about 8 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/39,46\">",
"     39,46",
"    </a>",
"    ], an effect that is not more pronounced when given with antihypertensive drugs that also have vasodilator activity (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/47\">",
"     47",
"    </a>",
"    ]. A post hoc analysis of patients taking sildenafil noted a similar incidence of adverse events, including those related to blood pressure (hypotension, dizziness, and syncope) in sildenafil users taking concomitant antihypertensive drugs compared to those who were not [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    also dilates epicardial coronary arteries and, in patients with coronary heart disease, improves endothelial dysfunction and inhibits platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/49\">",
"     49",
"    </a>",
"    ]. Among patients with exercise-induced ischemia, sildenafil has a beneficial effect that is intermediate between that induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    and placebo. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Does sildenafil promote MI?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vardenafil and tadalafil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     Vardenafil",
"    </a>",
"    (Levitra) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    (Cialis) are more selective and more potent PDE-5 inhibitors than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    . Both drugs appear to be as effective as sildenafil for the treatment of erectile dysfunction. Tadalafil has the advantage of a longer duration of action, thereby allowing more spontaneity in sexual activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the cardiovascular effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    in men with heart disease are limited. These drugs, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , potentiate the hypotensive response to nitrates; this interaction lasts 24 hours with vardenafil and up to 48 hours with tadalafil [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/50\">",
"     50",
"    </a>",
"    ]. Thus, tadalafil and vardenafil are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    with concomitant nitrate use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    and alpha blocking agents can lead to symptomatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, these drugs should not be administered together.",
"   </p>",
"   <p>",
"    A slight prolongation of the QT interval has been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , but this is not thought to be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/51\">",
"     51",
"    </a>",
"    ]. However, vardenafil should not be used in men with congenital long QT syndrome or in those taking drugs that can cause the long QT syndrome (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Adverse interaction with nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important limitation is the",
"    <strong>",
"     contraindication",
"    </strong>",
"    to the use of PDE-5 inhibitors in patients taking nitrates of any form, regularly or intermittently [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43\">",
"     22,43",
"    </a>",
"    ]. The efficacy of PDE-5 inhibitors is based upon the role of nitric oxide-induced vasodilation (which is mediated by cyclic GMP) in initiating and maintaining an erection. Detumescence is associated with catabolism of cyclic GMP by type 5 cyclic GMP phosphodiesterase, which is blocked by these drugs. Nitrates also act by a cyclic GMP mechanism and can therefore potentiate the effects of PDE-5 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=see_link\">",
"     \"Nitrates in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Men treated with PDE-5 inhibitors and nitrates are at risk for severe hypotension and syncope. Support for this negative interaction comes from a randomized, placebo-controlled trial of patients with stable coronary artery disease who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    for five to seven days before a dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and from a second study in which sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    was given one hour before sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/52\">",
"     52",
"    </a>",
"    ]. Coadministration of sildenafil with either nitrate produced a significantly greater reduction in blood pressure (mean maximum reduction",
"    <span class=\"nowrap\">",
"     52/29",
"    </span>",
"    mmHg with isosorbide mononitrate and",
"    <span class=\"nowrap\">",
"     36/21",
"    </span>",
"    mmHg with sublingual nitroglycerin) compared to the nitrate alone (mean maximum reduction",
"    <span class=\"nowrap\">",
"     25/15",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     26/12",
"    </span>",
"    mmHg, respectively).",
"   </p>",
"   <p>",
"    If a man who has taken a PDE-5 inhibitor develops chest pain, nitrates should not be administered within 24 hours (or longer in patients with renal or hepatic dysfunction) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , 24 hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , or up to 48 hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43,50\">",
"     22,43,50",
"    </a>",
"    ]. This includes any form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (eg, sublingual, transdermal, and spray formulations);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    ; pentaerythritol tetranitrate or erythrityl tetranitrate; and amyl nitrate (which may be abused and known by various names, including \"poppers\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the risk associated with nitrates, PDE-5 inhibitors are typically well tolerated with only minor reductions in blood pressure in patients taking conventional antihypertensive drugs (eg, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta blockers, and diuretics), even when used in combination [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Does sildenafil promote MI?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction and sudden death have been described after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    therapy, but the relation to the drug is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. By November 1998, the United States Food and Drug Administration had received reports of 130 men who died within hours to days after taking sildenafil. Myocardial infarction was confirmed in 77, and 27 deaths were attributed to cardiac arrest. Seventy percent of the men had known cardiovascular disease and several were using a nitrate concurrently with sildenafil. Among patients taking a nitrate, a large and protracted reduction in systemic blood pressure and in coronary blood flow in arteries with a critical stenosis could lead to coronary ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as mentioned previously, sexual activity itself can trigger an MI (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk of MI after sex'",
"    </a>",
"    above). Thus, case reports of MI in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    may have been unrelated to the drug. Consistent with this hypothesis are the results of extensive postmarketing surveillance which have failed to demonstrate a significant association between sildenafil and cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/39,44,58-62\">",
"     39,44,58-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 4274 patients found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      did not increase the rate of serious cardiovascular events or MI [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another review limited to 357 patients with stable coronary disease not taking nitrates,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      did not increase the incidence of serious cardiovascular events or MI [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In data reported to the drug company involving 6527 patients, there was no increase in the incidence of all cause mortality or MI [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-crossover study of 69 men with MI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      was not associated with an increased risk of the event [",
"      <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    is generally well tolerated in men with severe coronary disease not using nitrates. This was illustrated in a study of 14 men with stable symptoms, but greater than 70 percent stenosis of at least one coronary artery, who underwent hemodynamic evaluation after a single dose of sildenafil (100 mg) at least 24 hours after the discontinuation of nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/46\">",
"     46",
"    </a>",
"    ]. Blood flow velocity and flow reserve were assessed using a Doppler guidewire and intracoronary adenosine administration. Although there were small decreases (&lt;10 percent) in systemic and pulmonary arterial pressures, there was no effect on intracardiac pressures, heart rate, cardiac output, peak coronary flow velocity, coronary artery diameter, or coronary vascular resistance. Coronary flow reserve increased by 13 percent in both stenotic and control arteries.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    also appears to be safe during exercise in patients with stable coronary disease. This was illustrated in a randomized controlled trial in which sildenafil had no effect on symptoms, exercise duration, or the development or severity of exercise-induced ischemia as detected by exercise echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other potential problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasodilator properties of PDE-5 inhibitors may produce an adverse effect in some patients with a hypertrophic cardiomyopathy. The decrease in preload and afterload can increase the outflow obstruction, culminating in an unstable hemodynamic state [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of their inhibition of phosphodiesterase, there was initial concern that PDE-5 inhibitors might possess milrinone-like arrhythmogenic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/65\">",
"     65",
"    </a>",
"    ]. However, the specific target of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    is type 5 cyclic GMP phosphodiesterase, which is not expressed in heart muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/66\">",
"     66",
"    </a>",
"    ]. Despite this, class III antiarrhythmic properties (ie, prolongation of cardiac repolarization) have been described with sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/67\">",
"     67",
"    </a>",
"    ]. This effect was seen with high doses, which can be achieved in vivo in patients with hepatic or renal impairment, after a drug overdose, or during concurrent therapy with another CYP3A",
"    <span class=\"nowrap\">",
"     substrate/inhibitor",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A small study of the concomitant administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    found that some patients developed symptomatic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/43\">",
"     43",
"    </a>",
"    ]. As a result, a labeling precaution advises against taking 50 or 100 mg of sildenafil within four hours of administration of alpha-blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43\">",
"     22,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for sexual dysfunction other than a PDE-5 inhibitor can be pursued in patients with stable cardiac disease. There are no specific cardiovascular effects of androgen replacement therapy, penile prostheses, or vacuum-assisted erection devices. Although there has been one case report of MI temporally associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40966?source=see_link\">",
"     alprostadil",
"    </a>",
"    penile injection, there is no cardiovascular contraindication to its use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/68\">",
"     68",
"    </a>",
"    ]. However, yohimbine, an alpha-2 receptor blocker, should be used with caution because of its cardiovascular side effects, including tachycardia and the potential for hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H711838039\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 scientific statement from the American Heart Association addressed the issue of sexual activity in patients with cardiovascular disease (CVD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/69\">",
"     69",
"    </a>",
"    ]. We agree with the following general recommendations made in that document:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual activity is reasonable for patients with CVD who, on clinical evaluation, are considered to be at low risk of developing cardiovascular complications.",
"     </li>",
"     <li>",
"      Sexual activity is reasonable for patients who can exercise &ge;3 to 5 METS (",
"      <a class=\"graphic graphic_table graphicRef66344 \" href=\"UTD.htm?36/56/37774\">",
"       table 5",
"      </a>",
"      ) without angina, excessive dyspnea, ischemic ST-segment changes, cyanosis, hypotension, or arrhythmia.",
"     </li>",
"     <li>",
"      Patients with unstable, decompensated,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe symptomatic CVD should defer sexual activity until their condition is stabilized and optimally managed.",
"     </li>",
"     <li>",
"      Patients with CVD who experience cardiovascular symptoms precipitated by sexual activity should defer sexual activity until their condition is stabilized and optimally managed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We also agree with the following specific recommendations, which allow for sexual activity in the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who are one or more weeks after uncomplicated myocardial infarction, if the patient is without cardiac symptoms during mild to moderate physical activity.",
"     </li>",
"     <li>",
"      Those who have undergone complete percutaneous coronary revascularization and are several days after the intervention if the vascular access site is without complications.",
"     </li>",
"     <li>",
"      Those who have undergone open heart (either coronary or noncoronary) surgery and are six to eight weeks post-operative if the sternotomy is well healed.",
"     </li>",
"     <li>",
"      Those with mild of moderate valvular heart disease and no or mild symptoms. However, those with severe or significantly symptomatic valvular disease should not participate until their condition is stabilized and optimally managed.",
"     </li>",
"     <li>",
"      Those with normally functioning prosthetic valves, successfully repaired valves, and successful transcatheter valve intervention.",
"     </li>",
"     <li>",
"      Those with pacemakers or implantable cardioverter defibrillators (implanted for primary prevention and assuming multiple shocks have not been received).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Those with atrial fibrillation or flutter and well-controlled ventricular rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=see_link\">",
"       \"Patient information: Heart attack recovery (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"       \"Patient information: Heart attack recovery (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity is associated with a moderate hemodynamic stress and increases the risk of MI. However, the absolute increase in risk is very small. In addition, risk modification can be accomplished with regular physical activity and possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and beta blocker use. Thus, patients with heart disease who are not deemed to be at high risk should be able to be sexually active after appropriate risk stratification and optimization of therapy and can be safely treated for sexual dysfunction. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk assignment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Both the Second Princeton Consensus Panel and a consensus statement from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association concluded that a PDE-5 inhibitor is safe for men with stable coronary artery disease who are not taking nitrates&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no clinical differences among the PDE-5 inhibitors with the exception of a prolonged duration of action with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    . Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    and tadalafil are not likely to be associated with increased cardiac risk compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , there is less clinical information related to the safety of these drugs in men with heart disease. Until such information is available, and because of its relatively shorter half-life, we recommend sildenafil for men with erectile dysfunction who have heart disease.",
"   </p>",
"   <p>",
"    The PDE-5 inhibitors are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    with any nitrate preparation and should not be taken with alpha-blocking agents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43\">",
"     22,43",
"    </a>",
"    ]. Cardiac patients should be counseled about the interaction with nitrates, even if a PDE-5 inhibitor is not currently prescribed. If a man who has taken a PDE-5 inhibitor develops chest pain, nitrates should not be administered within 24 hours (or longer in patients with renal or hepatic dysfunction) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , 24 hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , or up to 48 hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/22,43,50\">",
"     22,43,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    consensus statement also alerts physicians to the potentially hazardous cardiovascular effects of PDE-5 inhibitors in the following groups of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/15/8442/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with active coronary ischemia, even in those who are not taking nitrates (eg, positive exercise stress test for ischemia)",
"     </li>",
"     <li>",
"      Patients with heart failure and borderline low blood pressure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low volume status (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H15#H15\">",
"       \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'PDE-5 inhibitors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patients on a complicated multidrug antihypertensive drug regimen",
"     </li>",
"     <li>",
"      Patients taking drugs that prolong the half-life of PDE-5 inhibitors by blocking CYP3A4 (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"       table 4",
"      </a>",
"      ); on the other hand, drugs that induce CYP3A4, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , can be expected to reduce the effectiveness of these drugs (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/1\">",
"      Rampin O, Giuliano F. Central control of the cardiovascular and erection systems: possible mechanisms and interactions. Am J Cardiol 2000; 86:19F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/2\">",
"      Meston CM. Sympathetic nervous system activity and female sexual arousal. Am J Cardiol 2000; 86:30F.",
"     </a>",
"    </li>",
"    <li>",
"     Masters, WH, Johnson, VE. Human sexual response, Little, Brown, and Co, Boston 1966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/4\">",
"      BARTLETT RG Jr. Physiologic responses during coitus. J Appl Physiol 1956; 9:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/5\">",
"      Hellerstein HK, Friedman EH. Sexual activity and the postcoronary patient. Arch Intern Med 1970; 125:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/6\">",
"      Nemec ED, Mansfield L, Kennedy JW. Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J 1976; 92:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/7\">",
"      Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med 1984; 144:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/8\">",
"      DeBusk RF. Evaluating the cardiovascular tolerance for sex. Am J Cardiol 2000; 86:51F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/9\">",
"      Stein RA. Cardiovascular response to sexual activity. Am J Cardiol 2000; 86:27F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/10\">",
"      Stein RA. The effect of exercise training on heart rate during coitus in the post myocardial infarction patient. Circulation 1977; 55:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/11\">",
"      Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996; 275:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/12\">",
"      M&ouml;ller J, Ahlbom A, Hulting J, et al. Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 2001; 86:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/13\">",
"      Jackson G. Sexual intercourse and angina pectoris. Int Rehabil Med 1981; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/14\">",
"      Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol 2000; 86:14F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/15\">",
"      Kimmel SE. Sex and myocardial infarction: an epidemiologic perspective. Am J Cardiol 2000; 86:10F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/16\">",
"      Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993; 329:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/17\">",
"      Albert CM, Mittleman MA, Chae CU, et al. Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med 2000; 343:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/18\">",
"      Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/19\">",
"      Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol 1994; 23:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/20\">",
"      Mittleman MA, Maclure M, Sherwood JB, et al. Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation 1995; 92:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/21\">",
"      Ridker PM, Manson JE, Buring JE, et al. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990; 82:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/22\">",
"      Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/23\">",
"      Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/24\">",
"      Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract 1999; 53:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/25\">",
"      Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/26\">",
"      Drory Y, Kravetz S, Florian V, Weingarten M. Sexual activity after first acute myocardial infarction in middle-aged men: demographic, psychological and medical predictors. Cardiology 1998; 90:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/27\">",
"      Renshaw DC, Karstaedt A. Is there (sex) life after coronary bypass? Compr Ther 1988; 14:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/28\">",
"      Rosal MC, Downing J, Littman AB, Ahern DK. Sexual functioning post-myocardial infarction: effects of beta-blockers, psychological status and safety information. J Psychosom Res 1994; 38:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/29\">",
"      Papadopoulos C, Beaumont C, Shelley SI, Larrimore P. Myocardial infarction and sexual activity of the female patient. Arch Intern Med 1983; 143:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/30\">",
"      Drory Y, Kravetz S, Weingarten M. Comparison of sexual activity of women and men after a first acute myocardial infarction. Am J Cardiol 2000; 85:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/31\">",
"      Dhabuwala CB, Kumar A, Pierce JM. Myocardial infarction and its influence on male sexual function. Arch Sex Behav 1986; 15:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/32\">",
"      Papadopoulos C, Shelley SI, Piccolo M, et al. Sexual activity after coronary bypass surgery. Chest 1986; 90:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/33\">",
"      Petrie KJ, Weinman J, Sharpe N, Buckley J. Role of patients' view of their illness in predicting return to work and functioning after myocardial infarction: longitudinal study. BMJ 1996; 312:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/34\">",
"      Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86:41F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/35\">",
"      Friedman S. Cardiac disease, anxiety, and sexual functioning. Am J Cardiol 2000; 86:46F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/36\">",
"      Roose SP, Seidman SN. Sexual activity and cardiac risk: is depression a contributing factor? Am J Cardiol 2000; 86:38F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/37\">",
"      Papadopoulos C, Larrimore P, Cardin S, Shelley SI. Sexual concerns and needs of the postcoronary patient's wife. Arch Intern Med 1980; 140:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/38\">",
"      Roviaro S, Holmes DS, Holmsten RD. Influence of a cardiac rehabilitation program on the cardiovascular, psychological, and social functioning of cardiac patients. J Behav Med 1984; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/39\">",
"      Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86:57F.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/40\">",
"      Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/41\">",
"      Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/42\">",
"      Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/43\">",
"      Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/44\">",
"      Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83:29C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/45\">",
"      Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/46\">",
"      Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/47\">",
"      Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999; 83:21C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/48\">",
"      Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/49\">",
"      Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/50\">",
"      Kloner RA, Hutter AM, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/51\">",
"      Borer J, Armstrong P, Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. Circulation 2003; 107:e9052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/52\">",
"      Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/53\">",
"      Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001; 14:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/54\">",
"      Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004; 17:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/55\">",
"      Feenstra J, van Drie-Pierik RJ, Lacl&eacute; CF, Stricker BH. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/56\">",
"      Arora RR, Timoney M, Melilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med 1999; 341:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/57\">",
"      Ishikura F, Beppu S, Hamada T, et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 2000; 102:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/58\">",
"      Mittleman MA, Maclure M, Glasser DB. Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate. Am J Cardiol 2005; 96:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/59\">",
"      Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/60\">",
"      Shakir SA, Wilton LV, Boshier A, et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 322:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/61\">",
"      Bush HS. Safe use of sildenafil in patients with coronary artery disease. Cleve Clin J Med 2001; 68:349, 352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/62\">",
"      DeBusk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004; 93:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/63\">",
"      Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/64\">",
"      Stauffer JC, Ruiz V, Morard JD. Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy. N Engl J Med 1999; 341:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/65\">",
"      Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/66\">",
"      Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83:3C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/67\">",
"      Geelen P, Drolet B, Rail J, et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/68\">",
"      Vaidyanathan S, Krishnan KR. Myocardial infarction associated with intra-cavernosal administration of alprostadil in a patient with spinal cord injury and paraplegia. Spinal Cord 1996; 34:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/15/8442/abstract/69\">",
"      Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125:1058.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1541 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8442=[""].join("\n");
var outline_f8_15_8442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIOVASCULAR EFFECTS OF SEXUAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hemodynamic stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Response in stable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK OF MI AFTER SEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Modulation of risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Regular exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISK OF SEXUAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk assignment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intermediate or indeterminate risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - High risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SEXUAL DYSFUNCTION POST-MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT OF SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PDE-5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Sildenafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vardenafil and tadalafil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Adverse interaction with nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Does sildenafil promote MI?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other potential problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H711838039\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/3/44092\" title=\"table 1\">",
"      Management sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 3\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/56/37774\" title=\"table 5\">",
"      Energy spent with activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38341?source=related_link\">",
"      Erectile dysfunction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/29/2521?source=related_link\">",
"      Nitrates in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/6/37987?source=related_link\">",
"      Patient information: Heart attack recovery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_15_8443="Complix of screening in CRC";
var content_f8_15_8443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major complication rates of screening tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Screening test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perforation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium enema",
"       </td>",
"       <td>",
"        1/10,000",
"       </td>",
"       <td>",
"        1/50,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sigmoidoscopy",
"       </td>",
"       <td>",
"        9/10,000",
"       </td>",
"       <td>",
"        1/18,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy*",
"       </td>",
"       <td>",
"        2/1,000",
"       </td>",
"       <td>",
"        1/10,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Major complications are more frequent if polypectomy is performed.",
"    </div>",
"    <div class=\"reference\">",
"     Barium enema data adapted from Winawer, SJ, Fletcher, RH, Miller, L, et al. Gastroenterology 1997; 112:594. Sigmoidoscopy and colonoscopy data adapted from Gatto, NM, Frucht, H, Sundararajan, V, et al. J Natl Cancer Inst 2003; 95:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8443=[""].join("\n");
var outline_f8_15_8443=null;
var title_f8_15_8444="Vaccine true contraindications";
var content_f8_15_8444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    True contraindications to vaccine administration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Safety concern",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reason for contraindication and recommended action",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous anaphylactic reaction to a specific vaccine",
"       </td>",
"       <td>",
"        Avoid revaccination with the specific vaccine because of risk of recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of anaphylaxis to eggs or egg-protein",
"       </td>",
"       <td>",
"        Avoid measles, mumps, influenza and yellow-fever vaccine because these vaccines are prepared in embryonated chicken eggs or cultures and vaccines may contain residual egg protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous anaphylactic reaction to neomycin or streptomycin",
"       </td>",
"       <td>",
"        Avoid measles, mumps, rubella (MMR) vaccine because the MMR vaccine contains trace amounts of neomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of severe systemic reactions to the cholera, typhoid or plague vaccine",
"       </td>",
"       <td>",
"        Avoid revaccination with the specific vaccine because of risk of recurrence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults who are immunocompromised as a result of disease or its treatment",
"       </td>",
"       <td>",
"        Avoid live virus vaccines because there is an increased risk of viral replication in immunocompromised individual [See related card]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Household members of immunocompromised patients",
"       </td>",
"       <td>",
"        Avoid oral polio because vaccine induced disease (if it occurs) could be transmitted to the immunocompromised individual. This concern does not apply to the MMR vaccine because infection with vaccine strain measles, mumps or rubella is not transmitted to others [See related card]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnant women",
"       </td>",
"       <td>",
"        Avoid all live virus vaccines because of the potential risk to the fetus [See related card]",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American College Physicians Task Force on Adult Immunization and Infectious Diseases Society of America. Guide for adult immunization. Philadelphia. American College of Physicians, 1994; Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1994; 43:1; and Gershon, AA, Gardner, P, Peter, G, et al. Clin Infect Dis 1997; 25:782.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8444=[""].join("\n");
var outline_f8_15_8444=null;
var title_f8_15_8445="AIDS-defining conditions";
var content_f8_15_8445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=40\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=40\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AIDS-defining conditions according to age",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Only among children &lt;13 years",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial infections, multiple or recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoid interstitial pneumonia or pulmonary lymphoid hyperplasia complex*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        All ages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis of bronchi, trachea, or lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis of esophagus*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioidomycosis, disseminated or extrapulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcosis, extrapulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptosporidiosis, chronic intestinal (&gt;1 month's duration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age &gt;1 month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus retinitis (with loss of vision)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalopathy, HIV related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex: chronic ulcers (&gt;1 month's duration) or bronchitis, pneumonitis, or esophagitis (onset at age &gt;1 month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histoplasmosis, disseminated or extrapulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isosporiasis, chronic intestinal (&gt;1 month's duration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi sarcoma*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma, Burkitt (or equivalent term)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma, immunoblastic (or equivalent term)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma, primary, of brain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Mycobacterium avium",
"        </em>",
"        complex or",
"        <em>",
"         Mycobacterium kansasii",
"        </em>",
"        , disseminated or extrapulmonary*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"        (disseminated* or extrapulmonary*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Mycobacterium",
"        </em>",
"        , other species or unidentified species, disseminated* or extrapulmonary*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Pneumocystis jirovecii",
"        </em>",
"        pneumonia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive multifocal leukoencephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Salmonella",
"        </em>",
"        septicemia, recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis of brain, onset at age &gt;1 month*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wasting syndrome attributed to HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Only among adolescents and adults &ge;13 years",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical cancer, invasive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"        (pulmonary*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia, recurrent*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AIDS: Acquired Immunodeficiency Syndrome.",
"     <br>",
"      * Condition that might be diagnosed presumptively.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged &lt;18 months and for HIV infection and AIDS among children aged 18 months to &lt;13 years -- United States, 2008. MMWR Recomm Rep 2008; 57:1.",
"       </li>",
"       <li>",
"        1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43(No.12).",
"       </li>",
"       <li>",
"        1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(No.17).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8445=[""].join("\n");
var outline_f8_15_8445=null;
var title_f8_15_8446="Distribution of serum creatinine among US males and females";
var content_f8_15_8446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distribution of serum creatinine among United States males and females",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution of the serum creatinine (in mg/dL) among United States males and females for the years 1988 to 1994 (twelve years or older in age). Multiply values by 88.4 to convert to units of &micro;mol/L.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jones, CA, McQuillan, GM, Kusek, JW. Am J Kidney Dis 1998; 6:992",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8446=[""].join("\n");
var outline_f8_15_8446=null;
var title_f8_15_8447="Early development edema";
var content_f8_15_8447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early development of interstitial pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 479px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breakdown of the capillary endothelial barrier allows leakage of serum proteins into the interstitial space, undoing the osmotic gradient which normally promotes fluid reabsorption. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_15_8447=[""].join("\n");
var outline_f8_15_8447=null;
